{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !pip install torch torchvision torchaudio --index-url https://download.pytorch.org/whl/cu126\n",
    "# !pip install pandas\n",
    "# !pip install -U sentence-transformers\n",
    "# !pip install --upgrade transformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip show datasets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip uninstall torchvision\n",
    "# !pip install torchvision\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2.6.0+cu126\n",
      "12.6\n",
      "True\n",
      "PyTorch built with:\n",
      "  - GCC 11.2\n",
      "  - C++ Version: 201703\n",
      "  - Intel(R) oneAPI Math Kernel Library Version 2024.2-Product Build 20240605 for Intel(R) 64 architecture applications\n",
      "  - Intel(R) MKL-DNN v3.5.3 (Git Hash 66f0cb9eb66affd2da3bf5f8d897376f04aae6af)\n",
      "  - OpenMP 201511 (a.k.a. OpenMP 4.5)\n",
      "  - LAPACK is enabled (usually provided by MKL)\n",
      "  - NNPACK is enabled\n",
      "  - CPU capability usage: AVX512\n",
      "  - CUDA Runtime 12.6\n",
      "  - NVCC architecture flags: -gencode;arch=compute_50,code=sm_50;-gencode;arch=compute_60,code=sm_60;-gencode;arch=compute_70,code=sm_70;-gencode;arch=compute_75,code=sm_75;-gencode;arch=compute_80,code=sm_80;-gencode;arch=compute_86,code=sm_86;-gencode;arch=compute_90,code=sm_90\n",
      "  - CuDNN 90.5.1\n",
      "  - Magma 2.6.1\n",
      "  - Build settings: BLAS_INFO=mkl, BUILD_TYPE=Release, COMMIT_SHA=2236df1770800ffea5697b11b0bb0d910b2e59e1, CUDA_VERSION=12.6, CUDNN_VERSION=9.5.1, CXX_COMPILER=/opt/rh/gcc-toolset-11/root/usr/bin/c++, CXX_FLAGS= -D_GLIBCXX_USE_CXX11_ABI=1 -fvisibility-inlines-hidden -DUSE_PTHREADPOOL -DNDEBUG -DUSE_KINETO -DLIBKINETO_NOROCTRACER -DLIBKINETO_NOXPUPTI=ON -DUSE_FBGEMM -DUSE_PYTORCH_QNNPACK -DUSE_XNNPACK -DSYMBOLICATE_MOBILE_DEBUG_HANDLE -O2 -fPIC -Wall -Wextra -Werror=return-type -Werror=non-virtual-dtor -Werror=range-loop-construct -Werror=bool-operation -Wnarrowing -Wno-missing-field-initializers -Wno-type-limits -Wno-array-bounds -Wno-unknown-pragmas -Wno-unused-parameter -Wno-strict-overflow -Wno-strict-aliasing -Wno-stringop-overflow -Wsuggest-override -Wno-psabi -Wno-error=old-style-cast -Wno-missing-braces -fdiagnostics-color=always -faligned-new -Wno-unused-but-set-variable -Wno-maybe-uninitialized -fno-math-errno -fno-trapping-math -Werror=format -Wno-stringop-overflow, LAPACK_INFO=mkl, PERF_WITH_AVX=1, PERF_WITH_AVX2=1, TORCH_VERSION=2.6.0, USE_CUDA=ON, USE_CUDNN=ON, USE_CUSPARSELT=1, USE_EXCEPTION_PTR=1, USE_GFLAGS=OFF, USE_GLOG=OFF, USE_GLOO=ON, USE_MKL=ON, USE_MKLDNN=ON, USE_MPI=OFF, USE_NCCL=1, USE_NNPACK=ON, USE_OPENMP=ON, USE_ROCM=OFF, USE_ROCM_KERNEL_ASSERT=OFF, \n",
      "\n",
      "1\n",
      "GPU 0: Tesla V100-SXM2-32GB\n",
      "True\n"
     ]
    }
   ],
   "source": [
    "import torch\n",
    "print(torch.__version__)  \n",
    "print(torch.version.cuda)  \n",
    "print(torch.cuda.is_available())  \n",
    "import torch\n",
    "print(torch.__config__.show())\n",
    "print(torch.cuda.device_count())  \n",
    "for i in range(torch.cuda.device_count()):\n",
    "    print(f\"GPU {i}: {torch.cuda.get_device_name(i)}\")  \n",
    "print(torch.backends.cudnn.enabled)  \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>fileid</th>\n",
       "      <th>filename</th>\n",
       "      <th>AccessionID</th>\n",
       "      <th>pmid</th>\n",
       "      <th>MID</th>\n",
       "      <th>title</th>\n",
       "      <th>registries</th>\n",
       "      <th>tag</th>\n",
       "      <th>isNCT</th>\n",
       "      <th>haveAlready</th>\n",
       "      <th>isReal</th>\n",
       "      <th>NCTclean</th>\n",
       "      <th>section</th>\n",
       "      <th>altsection</th>\n",
       "      <th>noLic</th>\n",
       "      <th>NLMPT</th>\n",
       "      <th>MTPT</th>\n",
       "      <th>TPscore</th>\n",
       "      <th>Country</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>925751</td>\n",
       "      <td>oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...</td>\n",
       "      <td>PMC10515754</td>\n",
       "      <td>37745325</td>\n",
       "      <td>PMC10515754</td>\n",
       "      <td>article &gt; back &gt; ack &gt; p &gt; ext-link</td>\n",
       "      <td>NCT00001360</td>\n",
       "      <td>ext-link</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NCT00001360</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>0</td>\n",
       "      <td>preprint</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>USA</td>\n",
       "      <td>2024.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>925752</td>\n",
       "      <td>oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>37622521</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>article &gt; body &gt; INTRODUCTION &gt; p</td>\n",
       "      <td>NCT02770716</td>\n",
       "      <td>p</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NCT02770716</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>retrospective studies|multicenter study</td>\n",
       "      <td>0.999005</td>\n",
       "      <td>USA</td>\n",
       "      <td>2023.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>925753</td>\n",
       "      <td>oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>37622521</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>article &gt; body &gt; INTRODUCTION &gt; p</td>\n",
       "      <td>NCT01143246</td>\n",
       "      <td>p</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NCT01143246</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>retrospective studies|multicenter study</td>\n",
       "      <td>0.983015</td>\n",
       "      <td>USA</td>\n",
       "      <td>2023.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>925754</td>\n",
       "      <td>oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>37622521</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>article &gt; body &gt; INTRODUCTION &gt; p</td>\n",
       "      <td>NCT02770716</td>\n",
       "      <td>p</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NCT02770716</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>retrospective studies|multicenter study</td>\n",
       "      <td>0.999005</td>\n",
       "      <td>USA</td>\n",
       "      <td>2023.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>925755</td>\n",
       "      <td>oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>37622521</td>\n",
       "      <td>PMC10749708</td>\n",
       "      <td>article &gt; body &gt; INTRODUCTION &gt; p</td>\n",
       "      <td>NCT01143246</td>\n",
       "      <td>p</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>NCT01143246</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>retrospective studies|multicenter study</td>\n",
       "      <td>0.983015</td>\n",
       "      <td>USA</td>\n",
       "      <td>2023.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   fileid                                           filename  AccessionID  \\\n",
       "0  925751  oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...  PMC10515754   \n",
       "1  925752  oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...  PMC10749708   \n",
       "2  925753  oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...  PMC10749708   \n",
       "3  925754  oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...  PMC10749708   \n",
       "4  925755  oa_comm_xml.incr.2024-06-28.tar.gz:PMC010xxxxx...  PMC10749708   \n",
       "\n",
       "       pmid          MID                                title   registries  \\\n",
       "0  37745325  PMC10515754  article > back > ack > p > ext-link  NCT00001360   \n",
       "1  37622521  PMC10749708    article > body > INTRODUCTION > p  NCT02770716   \n",
       "2  37622521  PMC10749708    article > body > INTRODUCTION > p  NCT01143246   \n",
       "3  37622521  PMC10749708    article > body > INTRODUCTION > p  NCT02770716   \n",
       "4  37622521  PMC10749708    article > body > INTRODUCTION > p  NCT01143246   \n",
       "\n",
       "        tag  isNCT  haveAlready  isReal     NCTclean       section  \\\n",
       "0  ext-link      1            0       1  NCT00001360         Other   \n",
       "1         p      1            0       1  NCT02770716  Introduction   \n",
       "2         p      1            0       1  NCT01143246  Introduction   \n",
       "3         p      1            0       1  NCT02770716  Introduction   \n",
       "4         p      1            0       1  NCT01143246  Introduction   \n",
       "\n",
       "     altsection  noLic     NLMPT                                     MTPT  \\\n",
       "0         Other      0  preprint                                      NaN   \n",
       "1  Introduction      0       NaN  retrospective studies|multicenter study   \n",
       "2  Introduction      0       NaN  retrospective studies|multicenter study   \n",
       "3  Introduction      0       NaN  retrospective studies|multicenter study   \n",
       "4  Introduction      0       NaN  retrospective studies|multicenter study   \n",
       "\n",
       "    TPscore Country    year  \n",
       "0       NaN     USA  2024.0  \n",
       "1  0.999005     USA  2023.0  \n",
       "2  0.983015     USA  2023.0  \n",
       "3  0.999005     USA  2023.0  \n",
       "4  0.983015     USA  2023.0  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df = pd.read_csv('PMCXML6.tsv', delimiter='\\t')\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.0"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def jaccard_similarity(set1, set2):\n",
    "    intersection = len(set1 & set2)\n",
    "    union = len(set1 | set2)\n",
    "    return intersection / union if union != 0 else 0\n",
    "\n",
    "jaccard_similarity({'Results', 'Results'}, {'Other', 'Conclusion'})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(['ack',\n",
       "  'INTRODUCTION',\n",
       "  'INTRODUCTION',\n",
       "  'INTRODUCTION',\n",
       "  'INTRODUCTION',\n",
       "  'ack',\n",
       "  'ack',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'ref-list',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'Unlocking the potential of MSCs and exosomes in Dermatology: a promising cell-free therapeutic approach',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'p',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'ref-list',\n",
       "  'Discussion',\n",
       "  'Discussion',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'notes',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'T-TEER',\n",
       "  'T-TEER',\n",
       "  'TTVR',\n",
       "  'TTVR',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'ETHICS STATEMENTS',\n",
       "  'ETHICS STATEMENTS',\n",
       "  'DISCUSSION',\n",
       "  'DISCUSSION',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  '3 Results',\n",
       "  'article-meta',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Therapeutic intervention targeting lipid metabolism in cancer',\n",
       "  'Introduction',\n",
       "  'Introduction',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'T-cell-related immunotherapies in colorectal cancer',\n",
       "  'article-meta',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  'Method',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  'article-meta',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  '2 Materials and methods',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'ack',\n",
       "  'ack',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'p',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'ref-list',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'article-meta',\n",
       "  'Discussion',\n",
       "  'Discussion',\n",
       "  'ref-list',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Emerging strategies for delivery across the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Subjects and methods',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'Bypassing the BBB',\n",
       "  'article-meta',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'Supporting Information',\n",
       "  'Supporting Information',\n",
       "  'Supporting Information',\n",
       "  'Supporting Information',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'ETHICAL APPROVAL',\n",
       "  'ETHICAL APPROVAL',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'ref-list',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'article-meta',\n",
       "  '2 Methods',\n",
       "  '2 Methods',\n",
       "  '2 Methods',\n",
       "  '2 Methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Methods and materials',\n",
       "  'Methods and materials',\n",
       "  'Methods and materials',\n",
       "  'Methods and materials',\n",
       "  'Ethics statement',\n",
       "  'Ethics statement',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Pharmacological Routes Attempted and Early Clinical Trial Results',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Eosinophilic Asthma',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Chronic Rhinosinusitis with Nasal Polyps',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosionophilic Esophagitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Eosinophilic Granulomatosis with Polyangiitis',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'Hypereosinophilic Syndrome',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Patients and Methods',\n",
       "  'Patients and Methods',\n",
       "  'Patients and Methods',\n",
       "  'Patients and Methods',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'DISCUSSION',\n",
       "  'DISCUSSION',\n",
       "  'DISCUSSION',\n",
       "  'DISCUSSION',\n",
       "  'article-meta',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Mechanisms of Depolyploidization in PACCs',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Therapeutic Targeting of “Poly‐depolyploidization”',\n",
       "  'Materials & methods',\n",
       "  'Materials & methods',\n",
       "  'Materials & methods',\n",
       "  'Materials & methods',\n",
       "  'Financial & competing interests disclosure',\n",
       "  'Financial & competing interests disclosure',\n",
       "  'article-meta',\n",
       "  'p',\n",
       "  'Experimental Section',\n",
       "  'Experimental Section',\n",
       "  'Experimental Section',\n",
       "  'Experimental Section',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'Material and methods',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'Material and methods',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'Material and methods',\n",
       "  'CLINICAL TRIAL REGISTRATION',\n",
       "  'Material and methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Results',\n",
       "  'Results',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Materials and methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'Materials and Methods',\n",
       "  'article-meta',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'PATIENTS AND METHODS',\n",
       "  'PATIENTS AND METHODS',\n",
       "  'PATIENTS AND METHODS',\n",
       "  'PATIENTS AND METHODS',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'PATIENT AND DISEASE CHARACTERISTICS',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'MATERIALS AND METHODS',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Discussion',\n",
       "  'Discussion',\n",
       "  'Introduction',\n",
       "  'Introduction',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'ref-list',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'DISCUSSION',\n",
       "  'article-meta',\n",
       "  'DISCUSSION',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'METHODS',\n",
       "  'Supporting Information',\n",
       "  'Supporting Information',\n",
       "  '1. Introduction',\n",
       "  '1. Introduction',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'notes',\n",
       "  'notes',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'notes',\n",
       "  'article-meta',\n",
       "  '2. Method',\n",
       "  '2. Method',\n",
       "  '2. Method',\n",
       "  '2. Method',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'notes',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  'Introduction',\n",
       "  'Introduction',\n",
       "  'fn-group',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'ref-list',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'Bacterial infection',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'A look to the future: new therapy, ongoing studies and precision medicine in bronchiectasis',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'table-wrap',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  'Methods',\n",
       "  '资料与方法',\n",
       "  '资料与方法',\n",
       "  '资料与方法',\n",
       "  '资料与方法',\n",
       "  'article-meta',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  'p',\n",
       "  'p',\n",
       "  'article-meta',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  '1. Introduction',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  '1. Introduction',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  '4. Discussion',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  '4. Discussion',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'Role of cfDNA analysis in gynecologic cancer',\n",
       "  'article-meta',\n",
       "  'DISCUSSION',\n",
       "  'DISCUSSION',\n",
       "  'article-meta',\n",
       "  'article-meta',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  'Research design and methods',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  '2. Materials and Methods',\n",
       "  'notes',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'article-meta',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  'RESULTS',\n",
       "  ...],\n",
       " [{'Other'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods', 'Results'},\n",
       "  {'Methods', 'Results'},\n",
       "  {'Methods', 'Results'},\n",
       "  {'Methods', 'Results'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Introduction', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Results'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Introduction'},\n",
       "  {'Introduction'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Conclusions', 'Methods'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Introduction'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Introduction'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Methods', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Conclusions', 'Other'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Methods'},\n",
       "  {'Other'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Article-Metadata'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  {'Table'},\n",
       "  ...])"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "x = []\n",
    "sections = []\n",
    "for ind, row in df.iterrows():\n",
    "    parts = row['title'].split('>')\n",
    "    desired_text = parts[2].strip()\n",
    "    if desired_text != \"\":\n",
    "        x.append(desired_text)\n",
    "        sections.append({row['section'], row['altsection']})\n",
    "\n",
    "x, sections\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[1899478 1715907]\n",
      " [2388038 2796961]\n",
      " [4021796  748100]\n",
      " [2414530 2271532]\n",
      " [1900080 3859199]]\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "\n",
    "# 假設你的 list 是 data_list\n",
    "data_list = np.arange(4177918)  # 如果是數字\n",
    "# data_list = np.array(你的大數據list)  # 如果是任意內容\n",
    "\n",
    "# 產生 100,000 組隨機配對\n",
    "pairs = np.random.choice(data_list, size=(100000, 2), replace=False)\n",
    "\n",
    "# 檢查前 5 組\n",
    "print(pairs[:5])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('4. Therapeutic Targeting of E3 Ligases in Cancer Immunotherapy',\n",
       "  'Materials and methods',\n",
       "  0.5),\n",
       " ('Application of protein fusion inhibitors in clinical practice',\n",
       "  'Results',\n",
       "  0.0),\n",
       " ('Clinical translation', '4. Treatment of mHLH', 1.0),\n",
       " ('Methods', 'Viral Entry Inhibitors', 0.0),\n",
       " ('HCV-RELATED HCC miRNA-BASED APPROACHES', 'article-meta', 0.0),\n",
       " ('Results', 'Clinics and pathology', 0.0),\n",
       " ('ack', 'CONCLUSION', 0.0),\n",
       " ('The effect of antidepressant therapies on neuroplasticity and neuroprotection',\n",
       "  'Source of Cells for Retinal Transplantation',\n",
       "  0.0),\n",
       " ('Hedgehog signaling in AML', 'Methods', 0.0),\n",
       " ('article-meta', 'Introduction', 0.0),\n",
       " ('METHODS', 'table-wrap', 0.0),\n",
       " ('Signaling Pathways of RILI and Targeted Therapies for RILI',\n",
       "  'CLINICAL STUDIES OF TARGETED NEUROBLASTOMA THERAPY',\n",
       "  0.3333333333333333),\n",
       " ('PB0671', 'Introduction', 0.0),\n",
       " ('New perspectives in treatment of BMs', 'notes', 0.5),\n",
       " ('Background', 'Strategies of tumor treatment', 0.0),\n",
       " ('Methods', '2. Anti-PEG Abs in the clinic', 0.5),\n",
       " ('article-meta', 'p', 0.0),\n",
       " ('Discussion', 'Discussion', 1.0),\n",
       " ('Nicotine in diseases',\n",
       "  'Turning cold tumors hot: emerging immunotherapies for BCBMs',\n",
       "  0.0),\n",
       " ('2 Current clinical trial landscape', 'Results', 0.0),\n",
       " ('article-meta', 'Poster Presentations', 0.0),\n",
       " ('Rational and evaluation of CGRP targeted therapies',\n",
       "  '4 New Targets and Future Perspectives',\n",
       "  0.0),\n",
       " ('Publication Only', '2. Methods', 0.0),\n",
       " ('fn-group', 'Declarations', 0.5),\n",
       " ('ref-list',\n",
       "  'Life Span and Immature Form of Neutrophils',\n",
       "  0.3333333333333333),\n",
       " ('NK-Cell-Based Tumor Immunotherapy', '2. Materials and Methods', 0.0),\n",
       " ('3. Clinical Data',\n",
       "  '4. Innovative Strategies to Overcome Treatment Barriers Unique to Brain Metastases',\n",
       "  1.0),\n",
       " ('Circulating Inflammatory Mediators and Metaflammation in DKD',\n",
       "  '5. Pharmacologic Strategies for Factor XI Inhibition',\n",
       "  0.3333333333333333),\n",
       " ('Introduction', 'table-wrap', 0.0),\n",
       " ('CAR-T cell therapy in solid tumors: applications, challenges and recent advances',\n",
       "  'Targeting TAMs for successful immunotherapy of EOC',\n",
       "  0.0),\n",
       " ('Methods', '7. Targeting Immune Regulatory Networks', 0.0),\n",
       " ('RNA-based Tumor Therapeutics',\n",
       "  'Clinical studies of CD30-targeted therapy for lymphomas',\n",
       "  0.0),\n",
       " ('Methods', 'METHODS', 1.0),\n",
       " ('METHODS', 'Discussion', 0.0),\n",
       " ('Therapeutic interference with the DDR in pancreatic cancer',\n",
       "  'Treatment options for endocrine-resistant breast cancer',\n",
       "  0.0),\n",
       " ('MICROSATELLITE STATUS AND APPLICATION PROGRESS OF ICIS',\n",
       "  'Preventive and Acute Treatment of Atherothrombosis and Arterial Embolism: Novel Ways and Tailoring',\n",
       "  0.3333333333333333),\n",
       " ('Monoclonal antibodies in the treatment of amyloidosis', 'Background', 0.0),\n",
       " ('article-meta', 'notes', 0.0),\n",
       " ('Introduction', 'Future trials', 0.0),\n",
       " ('ref-list', 'Results', 0.0),\n",
       " ('DC-based Cancer Immunotherapy', 'Poster Presentations', 0.0),\n",
       " ('Patients and Methods', 'Introduction', 0.0),\n",
       " ('Methods', 'Antifungal Drugs in Clinical Development', 0.0),\n",
       " ('Methods', 'Introduction', 0.5),\n",
       " ('DISCUSSION', 'article-meta', 0.0),\n",
       " ('METHODS', 'notes', 0.0),\n",
       " ('Materials and Methods',\n",
       "  'Therapeutic Targets in Biliary Tract Cancers',\n",
       "  0.0),\n",
       " ('Future directions', 'METHODS', 0.0),\n",
       " ('RESULTS', '2. Therapeutic Targeting of the NF-κB Pathway in Cancer', 0.0),\n",
       " ('table-wrap', 'Clinical Trials', 0.0),\n",
       " ('p', 'Materials and Methods', 0.0),\n",
       " ('Methods', 'table-wrap', 0.0),\n",
       " ('NOVEL DRUGS CURRENTLY IN LATE-PHASE DEVELOPMENT', 'Methods', 0.5),\n",
       " ('Results', 'article-meta', 0.0),\n",
       " ('Haematologic cancers', 'Introduction', 0.0),\n",
       " ('Materials and Methods', 'table-wrap', 0.0),\n",
       " ('METHODS', 'Conclusions', 0.0),\n",
       " ('Methods', 'MATERIALS AND METHODS', 1.0),\n",
       " ('Methods',\n",
       "  'Programmed Death Ligand-1 Plus Cytotoxic T-Lymphocyte-Associated Protein 4Inhibitors',\n",
       "  0.5),\n",
       " ('Results', 'ENDOVASCULAR THROMBECTOMY IN LOW ASPECTS', 1.0),\n",
       " ('Discussion', '2. Oncogenic lncRNAs in breast cancer', 0.5),\n",
       " ('2. Materials and Methods',\n",
       "  'Methods: participants, interventions, and outcomes',\n",
       "  0.5),\n",
       " ('table-wrap',\n",
       "  'CD39/CD73/A2AR as a novel therapeutic target for combination therapy',\n",
       "  1.0),\n",
       " ('3. Macrophages in Tumor Therapy', '2. Materials and Methods', 0.0),\n",
       " ('ref-list', 'OVERVIEW OF CIRCRNAS INVOLVED IN HNC METASTASIS', 0.5),\n",
       " ('Materials and Methods',\n",
       "  '4. Mechanisms of Drug Withdrawal and Novel Therapeutic Options for Treating OUD',\n",
       "  0.0),\n",
       " ('Other approaches to targeting LAG-3, TIM-3, and TIGIT for immunotherapy',\n",
       "  'Methods',\n",
       "  0.5),\n",
       " ('JAK Inhibitors Approved for PsA and Under Investigation for Psoriasis',\n",
       "  'Methods',\n",
       "  1.0),\n",
       " ('Surface biomarkers have expanded significantly over the last decade',\n",
       "  'Types of Clinical Studies',\n",
       "  1.0),\n",
       " ('Previous Clinical Pursuits: Targeted Approaches Show Mixed Clinical Results',\n",
       "  'METHODS',\n",
       "  0.0),\n",
       " ('DMOADs based on the molecular mechanisms underlying OA pathogenesis',\n",
       "  'HSP90 INHIBITORS FOR CANCER TREATMENT',\n",
       "  0.3333333333333333),\n",
       " ('Overview of Pediatric DOAC Programs', 'Results', 0.0),\n",
       " ('Methods', 'RESULTS', 0.0),\n",
       " ('article-meta', '7 Challenges in developing selective TKIs', 0.0),\n",
       " ('3. Currently Used Nanomedicines for Cancer Treatment',\n",
       "  'Drug repurposing for COVID-19',\n",
       "  1.0),\n",
       " ('Materials and methods', 'Methods', 0.5),\n",
       " ('Methods', 'Discussion', 0.0),\n",
       " ('PHARMACOLOGICAL TREATMENT', 'Introduction', 0.3333333333333333),\n",
       " ('Results', 'Materials and methods', 0.0),\n",
       " ('Introduction', 'Materials and methods', 0.0),\n",
       " ('Materials and methods', 'Methods', 1.0),\n",
       " ('3. Patient-Derived Spheroids (PDS) and Organoids (PDO)', 'Methods', 0.5),\n",
       " ('CLINICAL TRIAL EVIDENCE FOR KIDNEY PROTECTION WITH GUIDELINE-DIRECTED MEDICAL THERAPIES',\n",
       "  'Materials and Methods',\n",
       "  0.5),\n",
       " ('Standard treatment for ovarian cancer', 'Background', 0.3333333333333333),\n",
       " ('article-meta', 'Poster Presentations', 0.0),\n",
       " ('article-meta',\n",
       "  '1. Microbiome in the Pathogenesis of Inflammatory Bowel Disease (IBD)',\n",
       "  0.0),\n",
       " ('Immunological targeted therapy', '1. Introduction', 0.0),\n",
       " ('Methods', 'article-meta', 0.0),\n",
       " ('4. Eosinophilic Gastritis and Enteritis', 'PARPi and RT in SCLC', 0.5),\n",
       " ('3. Advances in Potential Drugs Targeting GBM CSCs', 'Background', 0.0),\n",
       " ('Targeting leukemia cells', 'MATERIALS', 0.0),\n",
       " ('Selected Promising Central Nervous System Regenerative Therapies with Potential for Clinical Translation',\n",
       "  'MDSCs Targeting Improves T Cell-Based Immunotherapy Efficacy',\n",
       "  1.0),\n",
       " ('Main Text', '6. Therapeutic Perspectives', 0.0),\n",
       " ('Immunological treatment strategies against COVID-19',\n",
       "  'Clinical Studies for Cancer Therapies',\n",
       "  0.0),\n",
       " ('Treatment Selection for GEP NEN: Current Approach and Future Perspectives for Precision Therapy',\n",
       "  'Results',\n",
       "  0.0),\n",
       " ('GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS', 'ref-list', 1.0),\n",
       " ('Clinical use of metabolic inhibitors',\n",
       "  'Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy',\n",
       "  1.0),\n",
       " ('Oral Presentations', 'DISCUSSION', 0.3333333333333333),\n",
       " ('3. Strategies Focused on Tau Proteins', 'Poster Presentations', 0.0),\n",
       " ('Materials and Methods', 'Results', 0.0),\n",
       " ('4 Clinical Applications', 'Probe design for tumor-specificity', 0.0),\n",
       " ('Advent of an Early Combination Strategy in Type\\xa02 Diabetes',\n",
       "  'Secretion',\n",
       "  0.5),\n",
       " ('Methods', 'Immunotherapies', 1.0),\n",
       " ('Agents in clinical development to target the TGF-β pathway in oncology',\n",
       "  'CLINICAL PERSPECTIVES',\n",
       "  1.0),\n",
       " ('Discussion', 'Trial status', 0.3333333333333333),\n",
       " ('Discussion', 'Commentary', 1.0),\n",
       " ('Blood brain barrier penetrance', 'Nutrients and Viral Infections', 1.0),\n",
       " ('Cancer therapy using nanomaterials', 'Discussion', 0.0),\n",
       " ('ref-list', 'article-meta', 0.0),\n",
       " ('Background', 'Methods', 0.0),\n",
       " ('Understanding and overcoming therapeutic resistance to BRAF inhibitors for HCL',\n",
       "  'Development of Inhibitors Targeting the p53-MDM2-MDMX Loop',\n",
       "  0.3333333333333333),\n",
       " ('\\\\n', 'Arteriovenous Grafts', 0.0),\n",
       " ('table-wrap', 'CAR NK cell as a novel tool to target CSCs', 1.0),\n",
       " ('article-meta',\n",
       "  'Calcium Handling Proteins in Cardiac Hypertrophy and HF and Their Potential as Novel Therapeutic Targets',\n",
       "  0.0),\n",
       " ('Materials and Methods', 'Methods\\xa0and\\xa0materials', 1.0),\n",
       " ('DEVELOPMENT OF BIOLOGICS AND ON-GOING CLINICAL TRIALS TARGETING EPITHELIUM-DERIVED CYTOKINES',\n",
       "  'Methods',\n",
       "  0.0),\n",
       " ('3. Results', '3.', 0.0),\n",
       " ('Exosomes for delivery of natural products', 'Poster Presentations', 0.5),\n",
       " ('Results', 'METHODS', 0.0),\n",
       " ('11. Present and future of immunotherapy in head and neck cancer',\n",
       "  '1. Introduction',\n",
       "  0.0),\n",
       " ('table-wrap', '3. Emergence of Immunotherapy in HNSCC', 0.0),\n",
       " ('2. Overview of Pancreatic Cancer', 'Poster Abstracts', 0.0),\n",
       " ('Findings', '4. New Immunotherapy Drugs and Combinations', 0.0),\n",
       " ('2 Current clinical trial landscape', 'Materials and Methods', 0.5),\n",
       " ('Methods',\n",
       "  'Long Covid symptoms, effect on organs, and pathological mechanisms',\n",
       "  0.0),\n",
       " ('Killed Whole-Cell/Fragmented Vaccine Candidates',\n",
       "  'Poster Presentations',\n",
       "  0.0),\n",
       " ('3. Results', 'Background', 0.0),\n",
       " ('Methods', 'Materials and Methods', 0.5),\n",
       " ('Poster Discussion Session 1: Rhinitis', 'Posters', 0.3333333333333333),\n",
       " ('notes', 'Introduction', 0.0),\n",
       " ('Methods/design', 'Methods', 0.5),\n",
       " ('2. Materials and Methods', 'article-meta', 0.0),\n",
       " ('ref-list', 'ref-list', 0.5),\n",
       " ('Immune Checkpoint Inhibitors for Early-Stage NSCLC: Neoadjuvant/Adjuvant Trials',\n",
       "  '4 Immunotherapy in HNSCC/OPSCC',\n",
       "  0.3333333333333333),\n",
       " ('1. Introduction',\n",
       "  '4. Targets and Novel Treatments Options in Chondrosarcoma',\n",
       "  0.0),\n",
       " ('2. Methods', 'ref-list', 0.0),\n",
       " ('Subjects and methods', 'Precision medicine trials in Ph-like ALL', 0.0),\n",
       " ('Research design and methods', '2. Materials and Methods', 1.0),\n",
       " ('table-wrap', 'Scientific Summary', 0.0),\n",
       " ('Recent Developments and Current Challenges', 'Materials and Methods', 0.0),\n",
       " ('Therapeutic Considerations in Pancreatobiliary Cancers', 'Results', 0.0),\n",
       " ('Ongoing therapeutic strategies targeting Notch signaling in human malignancies',\n",
       "  '3. Pim Kinase and Cardiovascular Disease',\n",
       "  1.0),\n",
       " ('Notable set-backs', 'STAR★Methods', 0.0),\n",
       " ('table-wrap', 'article-meta', 0.0),\n",
       " ('Pharmacokinetic Effects of Intrinsic Factors in Special Populations',\n",
       "  'Introduction',\n",
       "  0.0),\n",
       " ('4. Discussion', 'article-meta', 0.0),\n",
       " ('Treatment strategies of NAFLD', 'RESULTS', 0.0),\n",
       " ('4. AMPAR pharmacotherapies: past, present, and future',\n",
       "  'HDACi as Potential Therapeutic Agents for Treatment of Neurological Disorders',\n",
       "  0.0),\n",
       " ('ANTIGEN GENERATION, PRESENTATION, RELEASE AND CAPTURE',\n",
       "  'Background knowledge of CAFs',\n",
       "  1.0),\n",
       " ('3. Marine Compounds and Type 2 Diabetes Mellitus',\n",
       "  'Rational therapeutic measures',\n",
       "  0.0),\n",
       " ('MAbs against STI pathogens', 'IMMUNOMODULATORY DRUGS', 1.0),\n",
       " ('Methods', 'Discussion', 0.0),\n",
       " ('PB0570', 'Introduction', 0.0),\n",
       " ('Other approaches to targeting LAG-3, TIM-3, and TIGIT for immunotherapy',\n",
       "  'Disclosures',\n",
       "  0.0),\n",
       " ('Introduction', 'Potential Antibiotics in Development', 0.0),\n",
       " ('Patients and Methods', 'ATMP development: the way forward', 0.5),\n",
       " ('Discussion',\n",
       "  'Monotherapy or combination therapy in urogenital tumors',\n",
       "  1.0),\n",
       " ('Results', '5 Regulatory approval and clinical translation', 0.0),\n",
       " ('Consensus recomendations',\n",
       "  'Immunotherapy in breast cancer management',\n",
       "  0.0),\n",
       " ('Favoured interactions',\n",
       "  'Signaling pathways driving NAFL/NASH development and related therapeutic targets',\n",
       "  0.3333333333333333),\n",
       " ('Current applications of combination immunotherapy in gastrointestinal tumors',\n",
       "  'Efficacy and safety of immunotherapy for NSCLC',\n",
       "  0.3333333333333333),\n",
       " ('CircRNAs and cancer or tumor',\n",
       "  '8. Stereotactic Radiotherapy: A Confounding Factor',\n",
       "  0.5),\n",
       " ('CASE PRESENTATION',\n",
       "  'Clinical perspective regarding Treg/IL-17-producing Treg/Th17 cell axis modulation in BC cancer',\n",
       "  0.3333333333333333),\n",
       " ('Results', 'Vasopressors', 0.0),\n",
       " ('3 Preclinical and clinical trials of DDR inhibitors in combination with ICIs in UC',\n",
       "  'Host-related biomarkers',\n",
       "  0.0),\n",
       " ('Methods', 'Discussion', 0.0),\n",
       " ('ref-list', 'article-meta', 0.0),\n",
       " ('Methods', '3. Fundamental Mechanisms of Immune Checkpoints', 0.0),\n",
       " ('Therapies in Development', 'Oral presentations', 0.0),\n",
       " ('Materials and Methods', 'Materials and Methods', 1.0),\n",
       " ('table-wrap', 'Administrative information', 1.0),\n",
       " ('Introduction', '3. Results', 0.0),\n",
       " ('Materials and methods', 'Treatment of DLBCL-RT', 0.0),\n",
       " ('Strategies for targeting macrophages in the treatment of solid tumors',\n",
       "  'Poster Presentations',\n",
       "  0.0),\n",
       " ('Antibody therapeutics undergoing first regulatory review in the US or EU',\n",
       "  'Anti-TGF-β Therapies and Their Poor Outcomes in Cancer Clinical Trials',\n",
       "  0.0),\n",
       " ('5. Diagnostics, Drug Design and Vaccine Candidates', 'table-wrap', 0.0),\n",
       " ('APPLICATION OF THE GC MOLECULAR PROFILE IN CLINICAL PRACTICE: PRECISION MEDICINE',\n",
       "  'Immunotherapy',\n",
       "  0.0),\n",
       " ('Methods',\n",
       "  'PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer',\n",
       "  0.0),\n",
       " ('Future anti-fibril therapies', 'MATERIALS AND METHODS', 0.0),\n",
       " ('Methods', 'MSC-based cell therapy', 0.5),\n",
       " ('table-wrap', 'Results', 1.0),\n",
       " ('2. Current Therapeutics and Drug Development', 'table-wrap', 1.0),\n",
       " ('Discussion', '4. Discussion', 0.0),\n",
       " ('table-wrap',\n",
       "  '3. Clinical Trials to Assess the Effectiveness of Anti-',\n",
       "  0.0),\n",
       " ('Methodology', 'Results', 1.0),\n",
       " ('table-wrap', 'RESULTS', 0.0),\n",
       " ('3. B-cell-Based Therapies in SLE', 'Materials and methods', 0.0),\n",
       " ('article-meta',\n",
       "  'Immune checkpoints: biological aspects and clinical studies',\n",
       "  0.0),\n",
       " ('DIFFERENT METHODS OF GENE DELIVERY SYSTEMS FOR CRISPR/CAS9‐BASED CELL IMMUNOTHERAPY',\n",
       "  'Results',\n",
       "  0.0),\n",
       " ('METHODS', 'Targeted therapies aiming RTKs', 0.0),\n",
       " ('2. Materials and Methods', 'Poster Presentations', 0.0),\n",
       " ('THERAPEUTIC INTERVENTIONS', 'article-meta', 0.0),\n",
       " ('Emerging therapies', 'Patients and methods', 0.0),\n",
       " ('ref-list', 'INTRODUCTION', 0.0),\n",
       " ('Intratumoral Immunotherapies', '2. Monoclonal Antibodies', 1.0),\n",
       " ('2. The Pharmacological Targeting of Histone Acetylation',\n",
       "  'Therapeutic options for cancer-chemotherapy-related anemia',\n",
       "  1.0),\n",
       " ('article-meta', 'article-meta', 1.0),\n",
       " ('2. Hepatocellular Carcinoma', '2. Methods', 0.5),\n",
       " ('Role of microbial derived metabolites and CVD',\n",
       "  '3. Targeted Drug Therapy Designed for the Chronic Wound Microenvironment',\n",
       "  1.0),\n",
       " ('Methods and design', '4. EPLICATION-INCOMPETENT, VECTORED VACCINES', 0.0),\n",
       " ('Methods', 'Main Text', 0.0),\n",
       " ('Bladder cancer', 'article-meta', 0.0),\n",
       " ('notes', 'Background', 0.0),\n",
       " ('New Treatments for Sickle Cell Anemia',\n",
       "  '2. Therapeutic Targeting of the NF-κB Pathway in Cancer',\n",
       "  0.0),\n",
       " ('Ongoing Clinical Trials', 'Clinical studies', 0.3333333333333333),\n",
       " ('ref-list', 'Introduction', 0.0),\n",
       " ('Methods',\n",
       "  'Therapeutically exploiting fatty acid metabolism in cancer',\n",
       "  0.0),\n",
       " ('2 Methods', 'Aberrant B cell pathways', 1.0),\n",
       " ('Statistical analysis', 'Methods', 0.5),\n",
       " ('3. Compounds undergoing phase III clinical development for TRD',\n",
       "  '9. Genotype',\n",
       "  0.5),\n",
       " ('5. Current Development Status of bsAb-Based ICEs', 'ref-list', 0.5),\n",
       " ('Discussion', '4. Materials and Methods', 0.0),\n",
       " ('BACKGROUND', 'Materials And Methods', 0.0),\n",
       " ('Methods', 'Menthol in clinical practice', 0.0),\n",
       " ('p', 'ref-list', 1.0),\n",
       " ('article-meta', 'Therapeutic potential of targeting TAMs', 0.0),\n",
       " ('Background',\n",
       "  'The implications of MDSCs in the treatment of hematologic malignancies',\n",
       "  1.0),\n",
       " ('DISCLOSURE', 'Hematological and Immunological System Diseases', 1.0),\n",
       " ('Immunotherapeutic strategies for mesothelioma', 'Introduction', 0.0),\n",
       " ('Development of PARP inhibitors in prostate cancer used alone or in combination',\n",
       "  'Results',\n",
       "  0.0),\n",
       " ('table-wrap', 'KEY CLINICAL TRIALS CONDUCTED BY THE SPONSOR', 1.0),\n",
       " ('ref-list', '4. Targeting the HGF/MET Axis', 0.5),\n",
       " ('INTRODUCTION', '7. Evaluation by external experts', 0.0),\n",
       " ('Results', 'Cellular rewiring in drug resistance', 0.0),\n",
       " ('Results', '3. PDT in Clinical Trials', 0.5),\n",
       " ('Therapeutic potential of Treg cells', 'Discussion', 0.3333333333333333),\n",
       " ('Practical issues to be addressed', 'Materials and methods', 0.5),\n",
       " ('Discussion', 'Methods', 0.0),\n",
       " ('IRT in unresectable LA-NSCLC', 'Results', 1.0),\n",
       " ('Early Clinical Strategy for MK‐2640', 'Molecular biomarkers', 1.0),\n",
       " ('Introduction', 'Discussion', 0.0),\n",
       " ('Renin-Angiotensin-Aldosterone System', 'Introduction', 0.0),\n",
       " ('Anti-Interleukin 23 (IL-23)', 'Methods', 0.0),\n",
       " ('Materials and Methods', 'RESULTS', 0.0),\n",
       " ('Clinical implications', 'Poster Presentations', 0.3333333333333333),\n",
       " ('5. Targeting HER2 in Gastric Cancer', '6. Management', 0.3333333333333333),\n",
       " ('Materials and Methods', 'EHF Oral Presentation', 0.5),\n",
       " ('Results', 'Results', 1.0),\n",
       " ('Results', 'CD4', 0.0),\n",
       " ('4. Therapeutic Strategies to Overcome the Lack of Immune Recognition in Ovarian Cancer',\n",
       "  'Methods',\n",
       "  0.5),\n",
       " ('p', 'ref-list', 1.0),\n",
       " ('3.SARS-CoV-2 Vaccine and Variants', 'Introduction', 0.0),\n",
       " ('5 Intracellular Signaling Pathways of CXCL7', 'article-meta', 0.0),\n",
       " ('Subjects and methods', 'Introduction', 0.5),\n",
       " ('1. Introduction', 'Results', 0.0),\n",
       " ('讨论', 'ref-list', 1.0),\n",
       " ('Clinical Applications', 'ref-list', 0.5),\n",
       " ('4. Clinical Targeted Treatment Combinations including RT and Perspectives',\n",
       "  '2 MAPK/ERK Pathway Inhibitors as Monotherapies',\n",
       "  0.5),\n",
       " ('Introduction',\n",
       "  'Update on Clinical Trials Testing Tumor-Targeting Monoclonal Antibodies',\n",
       "  0.0),\n",
       " ('article-meta', 'article-meta', 1.0),\n",
       " ('Methods', 'IV. RT BIOLOGY AND TARGETED THERAPY', 0.5),\n",
       " ('table-wrap', 'article-meta', 0.0),\n",
       " ('3. Results', 'Drug repurposing for COVID-19', 0.0),\n",
       " ('Methods', 'LOBEGLITAZONE CLINICAL PROFILE', 0.5),\n",
       " ('Nk Cell-Based Therapeutic Strategies To Overcome Resistance In Solid Tumors',\n",
       "  'Methods',\n",
       "  0.5),\n",
       " ('Discussion', 'Discussion', 0.0),\n",
       " ('Research registration unique identifying number (UIN)',\n",
       "  'THERAPEUTIC STRATEGIES TARGETING BCSC ECOSYSTEM FOR BREAST CANCER METASTASIS',\n",
       "  0.0),\n",
       " ('table-wrap', 'Genetic basis', 1.0),\n",
       " ('ref-list',\n",
       "  '4. Strategies to Improve CAR T Cell Therapy for Patients with CLL',\n",
       "  0.5),\n",
       " ('article-meta', 'Methods', 0.0),\n",
       " ('Radionuclides used for T-cell nuclear imaging',\n",
       "  'Double strand damage',\n",
       "  0.0),\n",
       " ('6. Agents and Strategies for Cancer Immunotherapy',\n",
       "  '4 Jakinibs and COVID-19',\n",
       "  0.3333333333333333),\n",
       " ('Therapeutic Implications of Targeting STATs',\n",
       "  'CAR-T cell therapy clinical trials in breast cancer',\n",
       "  0.0),\n",
       " ('3. Tumor Therapies Targeting Macrophages', 'ref-list', 0.5),\n",
       " ('app-group', 'Materials and methods', 0.0),\n",
       " ('Methods', 'Main Text', 0.0),\n",
       " ('Clinical treatment and research',\n",
       "  'Treatment Advances in Systemic Therapy',\n",
       "  0.0),\n",
       " ('Genome Engineering Technologies for Cancer Treatment', 'Methods', 0.5),\n",
       " ('6. Conclusions',\n",
       "  '5. TTFields Therapy Concomitant with Taxanes in NSCLC, Ovarian Cancer, and Pancreatic Cancer',\n",
       "  0.0),\n",
       " ('Scientific Summary', 'Treatment Against COVID-19', 0.0),\n",
       " ('METHODS', '4. Exosome Manufacturing Status and Challenges', 0.0),\n",
       " ('RESULTS',\n",
       "  'Applications of somatic stem cells in oral and maxillofacial repair and regeneration',\n",
       "  0.0),\n",
       " ('table-wrap', '2. Gene Therapy for the Liver Cancers', 0.0),\n",
       " ('Future directions', 'article-meta', 0.0),\n",
       " ('The future perspective and challenges for clinical translation of SFN',\n",
       "  'Methods',\n",
       "  0.0),\n",
       " ('Metabolic Basis of PAH',\n",
       "  'Introduction to Glycosphingolipids',\n",
       "  0.3333333333333333),\n",
       " ('Methods',\n",
       "  '5. Immunotherapy in Advanced Metastatic SyS: Selected Use of Immune Check Point Inhibitors and Adoptive Transfer of Engineered Immune Effectors',\n",
       "  0.5),\n",
       " ('Poster Presentations', 'article-meta', 0.0),\n",
       " ('Poster Session: Treatment', 'Results', 0.0),\n",
       " ('article-meta', 'METHODS', 0.0),\n",
       " ('Approaches to Gene Therapy',\n",
       "  'Therapeutic opportunities for endothelial senescence',\n",
       "  0.0),\n",
       " ('article-meta', 'The Clinical Applications of Try Metabolites in LC', 0.0),\n",
       " ('Standard housing temperature',\n",
       "  '3. Activating the Innate Immune System in Cancer Therapy',\n",
       "  1.0),\n",
       " ('Update on Clinical Trials', 'table-wrap', 1.0),\n",
       " ('4. Clinical Evidence of Bispecific Antibodies in Solid Malignancies',\n",
       "  'Melanoma Bridge',\n",
       "  0.3333333333333333),\n",
       " ('METHODS AND MATERIALS', 'Poster Presentations', 0.0),\n",
       " ('Diets',\n",
       "  'TGF-β Inhibitors for the Treatment of Cancers and Cardiac Fibrosis',\n",
       "  0.5),\n",
       " ('Methods', 'Antibody-based therapy', 0.5),\n",
       " ('METHODS', 'Results', 0.0),\n",
       " ('PAR modulators as targets for therapy', 'article-meta', 0.0),\n",
       " ('1. Introduction', 'Materials and Methods', 0.0),\n",
       " ('DISCUSSION', 'Immunology', 0.3333333333333333),\n",
       " ('fig',\n",
       "  'Relapsed/refractory follicular lymphoma-approved and investigational approaches',\n",
       "  0.5),\n",
       " ('8. New Drugs Available or under Development', 'table-wrap', 0.0),\n",
       " ('Methods', 'ref-list', 0.0),\n",
       " ('Treatments', 'Main Text', 0.0),\n",
       " ('THERAPEUTIC INTERVENTIONS', 'ref-list', 0.0),\n",
       " ('STAR★Methods', 'Main Text', 0.0),\n",
       " ('Introduction', 'Mechanisms of TKI resistance', 0.0),\n",
       " ('Bioengineering for personalized medicine', 'RESULTS', 0.0),\n",
       " (\"Authors' conclusions\", 'Treatment options – VNS in humans', 0.0),\n",
       " ('Poster Presentations', 'article-meta', 0.0),\n",
       " ('Emerging Treatments in R/R ATL', 'Methods', 0.5),\n",
       " ('Small-molecule agents targeting cytokine and chemokine pathways',\n",
       "  'MATERIALS AND METHODS',\n",
       "  0.0),\n",
       " ('ICI plus anti-angiogenesis therapy in clinical studies',\n",
       "  'Introduction',\n",
       "  0.0),\n",
       " ('T cell engagers', 'Introduction', 0.0),\n",
       " ('5. Future Perspectives',\n",
       "  'Agents for Special GIST Populations',\n",
       "  0.3333333333333333),\n",
       " ('table-wrap', 'Results', 0.0),\n",
       " ('Adoptive cell immunotherapy', 'Adaptive immune responses', 0.0),\n",
       " ('Results', 'Extra-cardiac stem cells', 1.0),\n",
       " ('Methods', 'Results', 0.0),\n",
       " ('CAR-T Related Toxicities', 'Discussion', 0.0),\n",
       " ('Antibodies that may enter regulatory review in late 2016 or 2017',\n",
       "  'ref-list',\n",
       "  0.5),\n",
       " ('MATERIALS AND METHODS', 'article-meta', 0.0),\n",
       " ('Methods', 'Results', 0.0),\n",
       " ('Main text', 'Results', 0.0),\n",
       " ('ref-list', 'Tumour immunotherapy strategies targeting Tregs', 0.0),\n",
       " ('2 Growth factors and cytokines', 'article-meta', 0.0),\n",
       " ('Posters', '2. Lp(a) Lowering Drugs under Clinical Development', 0.0),\n",
       " ('ref-list', 'MATERIALS AND METHODS', 0.0),\n",
       " ('Methods: participants, interventions and outcomes', 'fn-group', 0.0),\n",
       " ('4. Clinical Evidence of Combination Therapies with PI3K Pathway Inhibitors and Current Trials in Progress',\n",
       "  'PAIN',\n",
       "  0.3333333333333333),\n",
       " ('Immune Response Modulators', 'Main text', 0.0),\n",
       " ('Trial monitoring',\n",
       "  'Overview of Recent Clinical Trials Using PRP for the Treatment of AGA',\n",
       "  0.3333333333333333),\n",
       " ('Introduction', 'Methods', 0.0),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('table-wrap', 'TCR-T Cell Therapy', 1.0),\n",
       " ('Therapeutic targeting of immunological and cellular processes in MDR-TB',\n",
       "  'Different Vaccine Approaches Used in COVID-19 Vaccine Development',\n",
       "  1.0),\n",
       " ('Upcoming treatment options beyond conventional chemotherapy',\n",
       "  'Discussion',\n",
       "  0.0),\n",
       " ('Administrative information',\n",
       "  '3. Current Landscape and Challenges of ICIs in MSS mCRC',\n",
       "  0.0),\n",
       " ('NEW PHARMACOLOGIC MEASURES THAT QUANTIFY CUMULATIVE DRUG EXPOSURE',\n",
       "  'Activities of Polyphenols in Relevant Cancer-Driving Signaling Pathways',\n",
       "  0.3333333333333333),\n",
       " ('AL Cardiac Amyloidosis',\n",
       "  '2. Treatment of Ovarian Cancer & Implications of',\n",
       "  0.3333333333333333),\n",
       " ('METHODS', 'Methods', 1.0),\n",
       " ('REPURPOSED DRUGS IN CLINICAL TRIALS', 'Methods', 0.0),\n",
       " ('Conclusion and future perspectives',\n",
       "  'Clinical trials related to pancreatic cancer',\n",
       "  1.0),\n",
       " ('4. Auristatins',\n",
       "  'Prospective therapeutic strategies post cdk4/6 inhibition',\n",
       "  0.3333333333333333),\n",
       " ('2. Metal-Based Nanoparticles',\n",
       "  'CLINICAL TRIALS OF FECAL MICROBIOTA TRANSPLANT FOR CANCER THERAPY',\n",
       "  0.0),\n",
       " ('Dermatomyositis', 'DISCUSSION', 0.5),\n",
       " ('Ethical approval and registration', 'article-meta', 0.0),\n",
       " ('Methods', 'Future clinical trials', 0.0),\n",
       " ('3. Cancer Immunotherapeutic Strategies',\n",
       "  '1. Cancer Chemoimmunotherapy',\n",
       "  1.0),\n",
       " ('Materials and Methods', '3. Non-Transplant Eligible Patients', 0.5),\n",
       " ('Methods', 'Immune-Targeting Treatments', 0.5),\n",
       " ('Patients and Methods', 'table-wrap', 0.0),\n",
       " ('Methods', 'Matrix components as therapeutic targets for cancer', 0.0),\n",
       " ('INTRODUCTION', 'Methods', 0.0),\n",
       " ('DISCUSSION', 'table-wrap', 0.0),\n",
       " ('COVALENT‐BINDING TYPE FLT3 INHIBITOR', '4. Experimental Section', 0.5),\n",
       " ('Materials and Methods',\n",
       "  'Molecular mechanisms repurposing non-oncology drugs in cancer therapy',\n",
       "  0.0),\n",
       " ('Introduction', 'EVIDENCE ON NAC IN LOCALLY AGC', 1.0),\n",
       " ('Background', '2. Types of Stem Cell and Their Clinical Studies', 0.0),\n",
       " ('Role of Surgery with Immunotherapy and Novel Immune Enhancing Agents',\n",
       "  'RESULTS',\n",
       "  0.0),\n",
       " ('METHODS', 'FA treatment', 0.5),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('2. Micronutrients',\n",
       "  '2. Receptor tyrosine kinase and downstream signaling pathway inhibitors',\n",
       "  0.5),\n",
       " ('Posters', 'table-wrap', 0.0),\n",
       " ('Methods', '3. Transcript-Targeted Therapies for Genetic Diseases', 0.0),\n",
       " ('TREATMENT', 'table-wrap', 0.0),\n",
       " ('CLOSING REMARKS AND FUTURE PERSPECTIVE', 'p', 0.0),\n",
       " ('Introduction',\n",
       "  'Therapeutic landscape of high risk and relapsed/refractory multiple myeloma in the era of personalized medicine',\n",
       "  0.0),\n",
       " ('Discussion',\n",
       "  '2 Mechanisms of anoikis resistance and potential therapies',\n",
       "  1.0),\n",
       " ('RECENTLY APPROVED NOVEL DRUGS', 'PATIENTS AND METHODS', 0.0),\n",
       " ('2. Abstracts Speakers',\n",
       "  '2. SABR Rationale and Patient Selection in Localized RCC',\n",
       "  0.5),\n",
       " ('Methods', 'Drug Discovery and Development Programs', 0.5),\n",
       " ('table-wrap', 'Method', 0.0),\n",
       " ('2. Selective CDK4/6i', 'ref-list', 0.5),\n",
       " ('Immunosuppressive and immunostimulatory IL-2 therapies',\n",
       "  'Viral Entry Inhibitors',\n",
       "  0.0),\n",
       " ('Trial monitoring', 'Materials and Methods', 0.5),\n",
       " ('table-wrap', 'article-meta', 0.0),\n",
       " ('Methods', 'The involvement of TAMs in responses to ICB therapies', 0.0),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('Introduction', 'CLINICAL STUDIES OF TARGETED NEUROBLASTOMA THERAPY', 0.0),\n",
       " ('Methods', 'Immunotherapeutic strategies', 0.0),\n",
       " ('Discussion', '4.5 Treatment', 0.3333333333333333),\n",
       " ('table-wrap',\n",
       "  'Advances in AD drug development focused on tau pathology and neuroinflammation',\n",
       "  1.0),\n",
       " ('Discussion', 'Results', 0.0),\n",
       " ('5. Combination Immune Checkpoint Inhibitors Trials',\n",
       "  '4. Materials and Methods',\n",
       "  0.5),\n",
       " ('Targeting RS as Radiation Sensitizer', 'Introduction', 0.0),\n",
       " ('4. Anti-Angiogenic Therapy', 'Belimumab', 0.5),\n",
       " ('Background', 'Discussion', 0.0),\n",
       " ('RESULTS', 'article-meta', 0.0),\n",
       " ('Pharmacological WM targets in treatment resistant schizophrenia: human studies',\n",
       "  'Dysregulation in the DNA methylation machinery; a missing piece in the puzzle of human diseases',\n",
       "  1.0),\n",
       " ('Result', 'Review', 0.0),\n",
       " ('article-meta', 'STAR★Methods', 0.0),\n",
       " ('table-wrap', 'Materials and Methods', 0.0),\n",
       " ('Adjuvant therapy', 'article-meta', 0.0),\n",
       " ('Failed mAbs in Progressive Multiple Sclerosis with Otherwise Approved and Working Compounds',\n",
       "  'Conclusions and future directions',\n",
       "  0.0),\n",
       " ('ESR1 mutations and selective estrogen receptor modulators and antagonists',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('METHODS',\n",
       "  '2. Neoadjuvant anti-PD-1/PD-L1 therapy according to cancer types',\n",
       "  0.3333333333333333),\n",
       " ('Anti-IL-4 & 13', 'Main text of the review', 0.5),\n",
       " ('Methods', 'STAR★Methods', 1.0),\n",
       " ('EHF ORAL PRESENTATIONS',\n",
       "  'Future biologics for chronic eosinophilic rhinosinusitis',\n",
       "  0.3333333333333333),\n",
       " ('INTRODUCTION', 'Immune Checkpoint on T Lymphocytes', 1.0),\n",
       " ('Current immunotherapeutic approaches for pediatric solid tumors',\n",
       "  'Scheme and Table',\n",
       "  0.0),\n",
       " ('Tau-Directed Therapeutics: Lack of Success to Date, but Reasons for Optimism',\n",
       "  'Discussion',\n",
       "  0.0),\n",
       " ('Oral Presentations',\n",
       "  '6. Peptide/Protein Drugs for Eye Diseases in Clinical Trials',\n",
       "  0.3333333333333333),\n",
       " ('Discussion', 'Discussion', 1.0),\n",
       " ('Results', '7. Targeting p53-dependent Nucleolar Stress Pathway', 0.0),\n",
       " ('Vaccine response in patients with MS on DMTs',\n",
       "  'Immune checkpoints and checkpoint blockade strategies',\n",
       "  0.3333333333333333),\n",
       " ('Evidence from randomized clinical trials', 'Treatment', 0.0),\n",
       " ('DISCUSSION', '3. Management of CRV Infections', 0.3333333333333333),\n",
       " ('Discussion and Conclusions', 'Liposomes', 0.0),\n",
       " ('table-wrap', 'table-wrap', 1.0),\n",
       " ('Discussion', 'METHODS', 0.0),\n",
       " ('Introduction', 'Primary Study Objectives and Outcome:', 0.5),\n",
       " ('Introduction', 'Conclusions', 0.0),\n",
       " ('1. Introduction',\n",
       "  'EFFECTS OF SGLT‐2 INHIBITORS AND SGLT‐1/2 INHIBITORS AMONG PATIENTS WITH T1D',\n",
       "  0.0),\n",
       " ('THERAPEUTIC AGENTS TARGETING THE HER2 SIGNALLING PATHWAY', 'Results', 0.0),\n",
       " ('2. Materials and Methods',\n",
       "  'Progress in mRNA cancer vaccines in preclinical and clinical settings',\n",
       "  0.0),\n",
       " ('KRAS mutations and cancer', 'Materials and Methods', 0.0),\n",
       " ('The HGF/c-MET pathway', 'fn-group', 0.0),\n",
       " ('ref-list',\n",
       "  'Clinical Trials Enrolling Regulatory T Cells',\n",
       "  0.3333333333333333),\n",
       " ('2. Methods', 'Discussion', 0.0),\n",
       " ('5. EMT as a New Target?', 'ref-list', 0.5),\n",
       " ('Methods', '3. BACE1 Inhibitors in Clinical Trials: What Happened?', 0.0),\n",
       " ('Histone deacetylase inhibitors', 'Discussion', 0.0),\n",
       " ('Methods', 'NK cell as a promising therapeutic target for cancer', 0.0),\n",
       " ('Therapeutic strategies targeting TAMs',\n",
       "  '3. Emerging Targeted Therapy for Malignant Glioma',\n",
       "  0.0),\n",
       " ('Adherence and protocol deviations {19}',\n",
       "  'Two main strategies for targeting oncogenic RAS',\n",
       "  0.0),\n",
       " ('fn-group',\n",
       "  '2. Spoiled for choice: points of intervention in the complement cascade',\n",
       "  0.5),\n",
       " ('Therapeutic Strategies: How Can We Harness Our Knowledge About TME to Improve PDAC Treatment?',\n",
       "  'Molecular Mechanisms of MSC-EVs in Lung Diseases',\n",
       "  0.0),\n",
       " ('p', '2 Immunotherapeutic Strategies Targeting the TME', 0.0),\n",
       " ('notes', 'INTRODUCTION', 0.0),\n",
       " ('ref-list',\n",
       "  'Findings and Discussion: Two Challenges For Conditional Approval Schemes',\n",
       "  1.0),\n",
       " ('article-meta', 'Results', 0.0),\n",
       " ('Ongoing Clinical Trials', 'INTRODUCTION', 0.0),\n",
       " ('2. Targets and Monoclonal Antibodies', 'Participants and Methods', 0.0),\n",
       " ('article-meta', 'Discussion', 0.0),\n",
       " ('TA-TMA-diagnosis, Risk Factors, and Treatment',\n",
       "  'ref-list',\n",
       "  0.3333333333333333),\n",
       " ('PCSK9 as a potential target for multiple disorders',\n",
       "  '2. Current Therapeutics and Drug Development',\n",
       "  1.0),\n",
       " ('Methods', 'Materials and Methods', 1.0),\n",
       " ('Perspective on Treatment', 'Targeting leukemia cells', 0.0),\n",
       " ('BEYOND GLYCEMIC CONTROL: THE USE OF ORAL HYPERGLYCEMIC AGENTS',\n",
       "  '2. Immunotherapy for the Treatment of Recurrent Glioblastoma',\n",
       "  1.0),\n",
       " ('table-wrap', '1. Cyclin Dependent Kinase 4/6 (CDK4/6) inhibition', 0.0),\n",
       " ('table-wrap', 'table-wrap', 1.0),\n",
       " ('Case presentation', 'Methods', 0.5),\n",
       " ('5. Treatment Strategies', '4 Discussion', 0.3333333333333333),\n",
       " ('Targeting Anti-Apoptotic Bcl-2 Family Members in Lymphoma', 'Drugs', 0.0),\n",
       " ('table-wrap',\n",
       "  'IDO1 inhibitors and peptide vaccines in clinical trials',\n",
       "  1.0),\n",
       " ('ref-list', 'Future Directions for Advanced Disease', 0.0),\n",
       " ('Background',\n",
       "  'Current status and ongoing efforts for immunotherapy in gastrointestinal cancers',\n",
       "  0.0),\n",
       " ('article-meta', 'Results', 0.0),\n",
       " ('Poster Presentations', 'ref-list', 0.5),\n",
       " ('Results', 'Targeting the PI3K/Akt/mTOR pathway in the clinic', 0.0),\n",
       " ('Molecular characteristics in current treatment & identification of targets',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('table-wrap', 'MATERIALS AND METHODS', 0.0),\n",
       " ('Experimental', 'Novel and emerging treatments for triglycerides', 1.0),\n",
       " ('Limitations', 'Poster Presentations', 0.3333333333333333),\n",
       " ('6. Clinical Trials of MSC-Derived EVs in AD',\n",
       "  '5. Aptamers in On-Going or Completed Clinical Trials for Therapeutics',\n",
       "  1.0),\n",
       " ('1 Introduction',\n",
       "  'The role of B7-H3 in tumor vasculature and clinical treatment',\n",
       "  0.0),\n",
       " ('Introduction', 'Introduction', 0.0),\n",
       " ('PDT and anti-cancer immunity',\n",
       "  'Myocardial Injury: Implications on ICU Care',\n",
       "  1.0),\n",
       " ('table-wrap', 'Results & Discussion', 0.0),\n",
       " ('Scientific Summary', '4 Clinical Applications', 0.0),\n",
       " ('Stem/progenitor cell-based clinical trials for RD treatment',\n",
       "  'Environmental Intervention Strategies in the School',\n",
       "  0.3333333333333333),\n",
       " ('DISCUSSION', 'Tumor Microenvironment', 0.3333333333333333),\n",
       " ('METHODS', 'Methods', 1.0),\n",
       " ('Future Directions', 'article-meta', 0.0),\n",
       " ('Ethics Approval and Consent to Participate',\n",
       "  '4. Direct Cell Replacement Therapy for Retinal and Optic Nerve Diseases',\n",
       "  1.0),\n",
       " ('Materials and methods', 'ref-list', 0.0),\n",
       " ('Discussion',\n",
       "  '2. CTC: Challenges for the Management of Cancer Patients',\n",
       "  1.0),\n",
       " ('Discussion', 'Antibody drug conjugates targeting HER2', 0.0),\n",
       " ('M',\n",
       "  'TRANSLATION REGULATION BY THE INTEGRATED STRESS RESPONSE PATHWAY',\n",
       "  0.3333333333333333),\n",
       " ('Materials and methods', 'Methods', 0.0),\n",
       " ('Results', 'Construction of islet organoid', 0.0),\n",
       " ('article-meta', 'Reflecting on Future Directions', 0.0),\n",
       " ('article-meta', 'Targeting TME in cancer', 0.0),\n",
       " ('Novel and emerging obesity therapies', 'Materials and methods', 0.0),\n",
       " ('article-meta', '4. Inflammatory Mediators in DN', 0.0),\n",
       " ('Background',\n",
       "  '4. Simvastatin: A Member of the Statin Family of Cholesterol-Lowering Drugs',\n",
       "  0.3333333333333333),\n",
       " ('article-meta', '4. Discussion', 0.0),\n",
       " ('Future Directions', 'CLINICAL TRIALS', 0.0),\n",
       " ('PARPi and RT in SCLC',\n",
       "  'Molecular mechanisms repurposing non-oncology drugs in cancer therapy',\n",
       "  0.0),\n",
       " ('Patients, Materials and Methods',\n",
       "  'Traditional cardiovascular risk factors',\n",
       "  0.0),\n",
       " ('From Eosinophils to Monoclonal Antibodies', 'notes', 0.5),\n",
       " ('table-wrap', 'Background', 1.0),\n",
       " ('3. Cancer–Immunity Cycle Acceleration by Locoregional Therapies',\n",
       "  'Ethics statements',\n",
       "  0.3333333333333333),\n",
       " ('table-wrap',\n",
       "  '4 Clinical Application of PD-1/PD-L1 Blockade-Based Combination Treatment for Breast Cancer',\n",
       "  0.0),\n",
       " ('Antibody-Based Therapies', '3. Emerging Therapies and Therapeutics', 1.0),\n",
       " ('Method', 'Gastrointestinal health and disease', 0.0),\n",
       " ('Mutations in genes encoding histone proteins', 'ack', 0.5),\n",
       " ('Materials and methods', 'Discussion', 0.0),\n",
       " ('FLT3 INHIBITOR RESISTANCE', '5. Tumour-Associated Antigens (TAAs)', 0.5),\n",
       " ('2. Materials and Methods', 'Rituximab', 0.0),\n",
       " ('Methods', 'ref-list', 0.0),\n",
       " ('Method', 'Methods', 1.0),\n",
       " ('Discussion', 'Methods', 0.0),\n",
       " ('ref-list',\n",
       "  'CLINICAL STUDIES OF TARGETED NEUROBLASTOMA THERAPY',\n",
       "  0.3333333333333333),\n",
       " ('Methods', 'Materials and Methods', 1.0),\n",
       " ('article-meta', 'Anticoagulants and Anti-platelet Agents', 0.0),\n",
       " ('Pharmaceutical-Grade Cannabinoid Formulations', 'Results', 0.0),\n",
       " ('3 Preclinical and clinical trials of DDR inhibitors in combination with ICIs in UC',\n",
       "  'Results',\n",
       "  0.5),\n",
       " ('GUT-BRAIN AXIS DEREGULATION', 'Background', 0.0),\n",
       " ('INTERMITTENT FASTING IN CLINICAL STUDIES OF CANCER', 'Methods', 0.0),\n",
       " ('Results', 'ref-list', 0.0),\n",
       " ('Targeting Sirtuins as a Therapeutic Strategy in Clinical Trials',\n",
       "  'LAG-3',\n",
       "  0.0),\n",
       " ('Chimeric Antigen Receptor T-cell Therapy',\n",
       "  'Discussion',\n",
       "  0.3333333333333333),\n",
       " ('Results',\n",
       "  '4. State of the Art of AD Disease-Modifying Treatments (DMT)s',\n",
       "  0.0),\n",
       " ('ref-list', 'Methodology', 0.0),\n",
       " ('2. Materials and Methods', 'Methods', 1.0),\n",
       " ('Current Standards of Care for Mesothelioma Treatment', 'Results', 0.0),\n",
       " ('Epigenetic regulatory mechanisms', '3. Results', 0.0),\n",
       " ('Indolamines: Simple tryptamines', 'table-wrap', 0.0),\n",
       " ('Methods', 'DISCUSSION', 0.0),\n",
       " ('Materials and Methods', 'Conclusions', 0.0),\n",
       " ('Results', 'Background', 0.0),\n",
       " ('RESULTS', 'Results', 1.0),\n",
       " ('Results', 'TLR9', 0.0),\n",
       " ('article-meta', 'Combination of ablation and immunotherapy', 0.0),\n",
       " ('4. Discussion', '6. Potential Targets and Future Directions', 1.0),\n",
       " ('INTRODUCTION', 'article-meta', 0.0),\n",
       " ('Treatment', 'AF treatment trials: Filling in the gaps', 0.0),\n",
       " ('Results', 'Introduction', 0.0),\n",
       " ('4. Inhibitors of CDK9', 'Methods', 0.0),\n",
       " ('Methods', 'Materials and methods', 0.5),\n",
       " ('Diagnostic Imaging of Prostate Cancer Patients With Disseminated Disease',\n",
       "  'Pharmacologic treatments: immunotherapy',\n",
       "  1.0),\n",
       " ('5. Clinical Studies of Early Interventions', 'Methods', 0.5),\n",
       " ('Introduction', 'table-wrap', 0.0),\n",
       " ('Introduction', 'Current Trials', 0.0),\n",
       " ('Therapeutic Potential of Targeting DPP4 in Diabetic Patients With COVID-19',\n",
       "  'Introduction',\n",
       "  0.0),\n",
       " ('Identification of SCCOHT therapeutic candidates', 'Methods', 0.0),\n",
       " ('article-meta', '2. Current Therapeutics and Drug Development', 0.0),\n",
       " ('Methods', 'Materials and methods', 1.0),\n",
       " ('3 OV in combination therapy regimen', 'IL-2', 0.5),\n",
       " ('table-wrap', '5. Targetable Molecular Pathways', 0.0),\n",
       " ('Ischaemic postconditioning',\n",
       "  'Update on Clinical Trials Testing Immunogenic Cell Death Inducers',\n",
       "  0.5),\n",
       " ('Methods',\n",
       "  'Promising targetable molecules in diffuse-type gastric cancer',\n",
       "  0.0),\n",
       " ('Materials and methods', 'NACT AND CLINICALLY POSITIVE AXILLA', 0.5),\n",
       " ('ref-list', 'BCMA-targeted CAR T cell trials', 0.3333333333333333),\n",
       " ('article-meta', '3. Antibody Based Therapies', 0.0),\n",
       " ('Other PARP inhibitors in clinical trials', 'article-meta', 0.0),\n",
       " ('Methods', 'Novel therapeutic strategies', 0.0),\n",
       " ('Vaccine candidate types', 'Methods', 0.0),\n",
       " ('HER2: BEYOND TRASTUZUMAB', 'article-meta', 0.0),\n",
       " ('Materials and Methods', '5. Diagnostic and Therapeutic Approaches', 0.5),\n",
       " ('Gene-modified T cell therapy',\n",
       "  'Mechanisms underlying edema formation',\n",
       "  0.0),\n",
       " ('Inpatient versus outpatient infusion', 'Introduction', 0.0),\n",
       " ('M', '4. Aromatase Inhibitors', 0.5),\n",
       " ('Results', 'First line therapy', 0.0),\n",
       " ('ADCs targeting Tregs in the TME',\n",
       "  'Immunotherapy in Hepatocellular Carcinoma',\n",
       "  0.0),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('Results of available trials', 'Results', 1.0),\n",
       " ('Materials and methods', '2. Methods', 0.5),\n",
       " ('ref-list', 'Introduction', 0.0),\n",
       " ('Background', 'Targeting antigens', 1.0),\n",
       " ('8. Therapeutic Personalized Strategies for OCCC Focused on Hypercoagulation',\n",
       "  'The race for vaccine development',\n",
       "  0.0),\n",
       " ('ref-list', 'IL-15 dosage', 0.5),\n",
       " ('3. Results', 'article-meta', 0.0),\n",
       " ('Clinical Trials of Helminthic Therapy in Autoimmune Disease',\n",
       "  'DISCUSSION',\n",
       "  0.0),\n",
       " ('CHARACTERISTICS OF STUDIES',\n",
       "  'Clinical Management of Patients with Acquired Resistance to Gefitinib or Erlotinib',\n",
       "  0.0),\n",
       " ('8. HDAC Inhibitors in Kidney Diseases', 'Introduction', 0.0),\n",
       " ('Patients and methods',\n",
       "  '6. RNA Vaccines for Infectious Diseases: Where Do RNA Vaccines Stand in Clinical Trials?',\n",
       "  0.0),\n",
       " ('ref-list', '2. Results', 0.0),\n",
       " ('Methods',\n",
       "  '4. GSC Molecular Features Amenable for Therapeutic Intervention',\n",
       "  0.5),\n",
       " ('Results', 'AML: A Therapeutic Landscape in Transition', 1.0),\n",
       " ('BBV152 safety phase I trial', 'article-meta', 0.0),\n",
       " ('article-meta', 'Results', 0.0),\n",
       " ('Introduction',\n",
       "  '1. TARGETING EXTRACELLULAR INDUCERS THAT INITIATE THE EMT PROGRAM',\n",
       "  0.0),\n",
       " ('Interpretation', '2. Glycosphingolipids', 0.0),\n",
       " ('CLINICAL TRIAL FINDINGS', 'Introduction', 0.0),\n",
       " ('Materials and methods',\n",
       "  'THERAPEUTICS PRODUCTS WITH P53 STATUS AS A TARGET',\n",
       "  0.0),\n",
       " ('GENE THERAPY FOR INHERITED RETINAL DISORDERS', 'article-meta', 0.0),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('RNA therapeutics', 'Ongoing Clinical Trials for Non-Clear Cell RCC', 0.5),\n",
       " ('Antimalarial drugs', 'Introduction', 0.0),\n",
       " ('CLINICAL TRIALS', 'Treatment of primary HIV-1 infection', 0.0),\n",
       " ('Background', 'Results', 0.0),\n",
       " ('table-wrap',\n",
       "  'Immune-based therapeutic approaches and their current status in the treatment of rare cancers',\n",
       "  1.0),\n",
       " ('5. Eicosanoids in Renal Cancer', 'Results', 0.0),\n",
       " ('Materials and methods', 'Clinical features of uveal melanoma', 0.5),\n",
       " ('JAK INHIBITORS',\n",
       "  '5. Clinical Impact of Targeting CAF Activity',\n",
       "  0.3333333333333333),\n",
       " ('Results', 'table-wrap', 0.0),\n",
       " ('[IO Barrier] Impaired Tumor Recognition and Blunted Host Immune Response:',\n",
       "  'Results',\n",
       "  0.5),\n",
       " ('Methods/Design', 'STAR ★ METHODS', 1.0),\n",
       " ('3. Neurofibromatosis Type 2', 'INTRODUCTION', 0.0),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('Declarations', 'table-wrap', 0.0),\n",
       " ('Clinical data',\n",
       "  '3. Therapeutic Strategies after Progression on CDK4/6i Therapy',\n",
       "  0.0),\n",
       " ('article-meta', 'III. NANOTECHNOLOGY IN THERAPEUTICS', 0.0),\n",
       " ('II. Current Treatment Options for Glioblastoma',\n",
       "  'Novel Therapeutic Strategies',\n",
       "  0.0),\n",
       " ('SCLC的免疫治疗进展', '3. Results', 0.0),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('Methods', 'Clinical efficacy', 0.0),\n",
       " ('Results', 'app-group', 0.0),\n",
       " ('Introduction', 'Use of recombinant', 0.0),\n",
       " ('Results', '2. Methods', 0.0),\n",
       " ('Main Text', 'Platelet Inhibitors and Cardiac Surgery', 0.0),\n",
       " ('Subjects and methods', 'PATIENTS, MATERIALS, AND METHODS', 1.0),\n",
       " ('Anti-IgE Therapy', 'PRR agonists', 0.5),\n",
       " ('article-meta', 'Targeting leukemia cells', 0.0),\n",
       " ('Subjects and methods',\n",
       "  'Strategies for targeting macrophages in the treatment of solid tumors',\n",
       "  0.0),\n",
       " ('6. Other Clinical Applications of Electroporation in Melanoma',\n",
       "  'BODY',\n",
       "  0.0),\n",
       " ('Tyrosine Phosphatases as Targets in Immunotherapy',\n",
       "  'Pharmacologic Strategies to Target Myeloid Cells in Cancer',\n",
       "  1.0),\n",
       " ('Clinical Efficacy of Inhaled Formoterol in Patients with COPD',\n",
       "  'Frontline Therapy',\n",
       "  0.0),\n",
       " ('Methods', '2. Oligonucleotides as Therapeutic Agents', 0.0),\n",
       " ('Results', 'MATERIALS AND METHODS', 0.0),\n",
       " ('BAs in cholestatic liver diseases', 'Results', 1.0),\n",
       " ('3. S1R as a Therapeutic Target & Conclusions', 'table-wrap', 0.0),\n",
       " ('Materials and methods', 'fn-group', 0.0),\n",
       " ('Neoantigens-based therapeutic strategies',\n",
       "  'PMF MEGAKARYOCYTES ARE HYPOMORPHIC FOR',\n",
       "  0.0),\n",
       " ('Methods', '2. Materials and Methods', 1.0),\n",
       " ('Targeted Agents Tested in Combination With ICIs in HNC',\n",
       "  'Vaccine Based on the RBD Region',\n",
       "  1.0),\n",
       " ('Lamin Mutations Dilated Cardiomyopathy',\n",
       "  'Potential therapeutic targets for MM',\n",
       "  0.5),\n",
       " ('Materials and methods', 'Results', 0.0),\n",
       " ('4. Methods', 'Mechanism-based approaches', 0.0),\n",
       " ('table-wrap', '3 Non-viral nano delivery systems', 1.0),\n",
       " ('ONLINE METHODS', 'table-wrap', 0.0),\n",
       " ('2. Materials and Methods', '4. Treatment Options for CLL', 0.5),\n",
       " ('4. Peri-Operative Neuroprotection—Clinical Studies',\n",
       "  'Clinical implications',\n",
       "  0.3333333333333333),\n",
       " ('Results', 'Materials and methods', 0.0),\n",
       " ('BIGUANIDES', 'Pharmacokinetics in Special Populations', 0.5),\n",
       " ('5. Natural Killer Cells', 'table-wrap', 0.0),\n",
       " ('Material and methods', 'Materials and Methods', 1.0),\n",
       " ('Introduction', 'Introduction', 0.0),\n",
       " ('3. Work on Dolastatin Derivatives as Warheads Leading to FDA Approval of Adcetris',\n",
       "  'table-wrap',\n",
       "  0.0),\n",
       " ('Discussion', 'Background', 0.0),\n",
       " ('table-wrap', 'MATERIALS AND METHODS', 0.0),\n",
       " ('METHODS', 'ref-list', 0.0),\n",
       " ('Background', 'Therapeutic Strategies for Targeting EMP', 1.0),\n",
       " ('Background',\n",
       "  'Combination of PARP Inhibitors With Immunotherapies in Ovarian Cancer',\n",
       "  0.0),\n",
       " ('3. Targeting the Initiators', 'Results', 0.0),\n",
       " ('4. PRAME-Targeted Immunotherapy',\n",
       "  '2 Gene therapy in LSD: Clinical trials and literature review',\n",
       "  0.3333333333333333),\n",
       " ('LAG-3', 'Treatment strategies for COVID-19', 1.0),\n",
       " ('Subjects and methods', 'Methods', 1.0),\n",
       " ('Methods', 'Results', 0.0),\n",
       " ('fn-group', 'METHODS', 0.0),\n",
       " ('Cell Therapy', 'Introduction', 1.0),\n",
       " ('Methods/design', 'article-meta', 0.0),\n",
       " ('INTRODUCTION', 'Figure, Schemes and Tables', 1.0),\n",
       " ('Results:', 'CURRENT IMMUNOTHERAPEUTIC STRATEGIES IN GASTRIC CANCER', 0.0),\n",
       " ('table-wrap', '4 Interventions for cardiac fibrosis', 1.0),\n",
       " ('Discussion', '6. Human Papilloma Virus (HPV)', 0.5),\n",
       " ('Targeted DLL Therapy: Is It Effective and Safe?', '3. Results', 0.0),\n",
       " ('MATERIALS AND METHODS',\n",
       "  '3. Challenges for T Cells in the Tumor Microenvironment',\n",
       "  0.0),\n",
       " ('ref-list', 'article-meta', 0.0),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('Scientific rationale',\n",
       "  '9. Therapeutic Strategies against the Transcriptional Factors p53, HIF1, and c-Myc in Glioma',\n",
       "  0.5),\n",
       " ('CLOSING REMARKS AND FUTURE PERSPECTIVE', 'ref-list', 0.0),\n",
       " ('Oral Presentations', 'Methods', 0.0),\n",
       " ('table-wrap', 'Methods', 0.0),\n",
       " ('Results', '3. Results', 1.0),\n",
       " ('The IGF family in cancer', 'article-meta', 0.0),\n",
       " ('OTHER ALLERGY/IMMUNOLOGY', 'Methods', 0.0),\n",
       " ('miRNA-BASED THERAPEUTICS', '3. Discussion', 1.0),\n",
       " ('Novel Targets in Development',\n",
       "  '2 SYN antigen expression and adopted cell transfer',\n",
       "  0.5),\n",
       " ('Non-TKI Targeted Therapies', 'Results', 0.0),\n",
       " ('Materials and Methods', '2. Materials & Methods', 1.0),\n",
       " ('Discussion', 'Materials and Methods', 0.0),\n",
       " ('Methods: participants, interventions, and outcomes',\n",
       "  'Re-Purposed Drugs Can Help To Overcome GC- and Chemoresistance In All',\n",
       "  0.0),\n",
       " ('Clinical Statuses of bsAbs in Lung Cancer', '6. Human Defensins and', 0.5),\n",
       " ('Imaging Modalities for the Assessment of Myocardial Fibrosis',\n",
       "  'PIOGLITAZONE',\n",
       "  0.5),\n",
       " ('Clinical management of advanced AM: current and emerging strategies',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('ref-list', '4. Cell Therapies', 1.0),\n",
       " ('Delivery Strategies for Promising Small Interfering RNA Therapeutics in Gliomas',\n",
       "  'Discussion',\n",
       "  0.3333333333333333),\n",
       " ('Poster Presentations',\n",
       "  'Inhibitory Targets Beyond Immune Checkpoints',\n",
       "  0.3333333333333333),\n",
       " ('FROM THERAPEUTIC STANDPOINT', 'table-wrap', 0.0),\n",
       " ('Results', 'table-wrap', 1.0),\n",
       " ('Methods', '2. Materials and Methods', 1.0),\n",
       " ('Systems bioengineers and industry', 'JAK Inhibitors', 1.0),\n",
       " ('Designing a regimen to treat MDR-TB',\n",
       "  '4. Emerging Treatment Strategies',\n",
       "  0.3333333333333333),\n",
       " ('3. Profibrotic Cytokines',\n",
       "  'Pathways Targeted by Drug Screening and Drug Repositioning Approaches in Spinal Muscular Atrophy',\n",
       "  0.0),\n",
       " ('Targeting the VHL/HIF axis', '2. Materials and Methods', 0.0),\n",
       " ('Precision medicine and drug development',\n",
       "  'CELL GRAFTING IN PD: THE PIONEERING STUDIES (1979-1990)',\n",
       "  0.0),\n",
       " ('Methods', 'Methods and analysis', 0.5),\n",
       " ('Methods', '2. Materials and Methods', 1.0),\n",
       " ('Materials & methods', '2. Addressing Fratricide', 0.0),\n",
       " ('Future ADCs combination strategies in breast cancer',\n",
       "  'Materials and methods',\n",
       "  0.0),\n",
       " ('Introduction', 'article-meta', 0.0),\n",
       " ('DISCUSSION', 'KRAS and Targeted Therapy', 1.0),\n",
       " ('Nucleus-targeted strategies for precision attack life blueprint',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('article-meta', 'Immunotherapy', 0.0),\n",
       " ('Therapiestrategien', 'MATERIAL AND METHODS', 0.0),\n",
       " ('table-wrap', 'article-meta', 0.0),\n",
       " ('Registration of research studies', 'article-meta', 0.0),\n",
       " ('table-wrap', 'General Conclusions', 1.0),\n",
       " ('p', 'Current Strategies Related to Immunotherapy in CRC', 0.5),\n",
       " ('“Old” Generation Immunotherapies', 'ncRNAs IN RADIATION RESPONSE', 0.5),\n",
       " ('Methods', 'INTRODUCTION', 0.0),\n",
       " ('Administrative information', 'Background', 1.0),\n",
       " ('Hodgkin lymphoma', 'SELECTIVE SMALL MOLECULE KINASE INHIBITORS', 0.0),\n",
       " ('Methods', 'Discussion', 0.0),\n",
       " ('Substance use disorders (SUDs)', '4. Discussion', 0.5),\n",
       " ('Subjects and Methods', 'EFFICACY OF ADCS IN BREAST CANCER', 0.0),\n",
       " ('ref-list', 'ref-list', 1.0),\n",
       " ('T-cell immunoglobulin and mucin domain-3', 'Aliskerin', 0.0),\n",
       " ('Melanoma Bridge', 'Discussion', 0.3333333333333333),\n",
       " ('article-meta', 'Methods', 0.0),\n",
       " ('Composition of LNPs',\n",
       "  'hiPSC-Derived Nscs as a Valuable Cell Source for Cell and Gene Therapy Approaches',\n",
       "  0.0),\n",
       " ('Results', 'Methods/design', 0.0),\n",
       " ('Clinical development', 'NK cells', 0.5),\n",
       " ('Ethics statements', 'article-meta', 0.0),\n",
       " ('Therapeutics and strategies for targeting FGF signaling',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('The Role of Innate Immunity in Specific Pathologies', 'Methods', 0.0),\n",
       " ('Current clinical application',\n",
       "  'Clinical Trial Information',\n",
       "  0.3333333333333333),\n",
       " ('Results',\n",
       "  '2. Clinical Landscape of MSCs Genetically Modified with Non-Viral Methods',\n",
       "  0.0),\n",
       " ('Materials and Methods', 'Anti-CSC Compounds in Clinical Development', 0.0),\n",
       " ('4. New Therapeutic Perspectives', 'table-wrap', 0.0),\n",
       " ('Targeting NK cells in hematologic malignancies', 'Methods', 0.0),\n",
       " ('Results', 'ack', 0.0),\n",
       " ('notes', '11. Clinical Cases', 0.0),\n",
       " ('Introduction', 'Targeted therapy in combination with chemotherapy', 0.0),\n",
       " ('4. Homologous Recombination Deficiency in uLMS', 'ref-list', 0.5),\n",
       " ('Patients, Materials and Methods',\n",
       "  'Azithromycin Effectiveness in COVID-19 Management',\n",
       "  0.0),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('Materials and methods', 'Adoptive transfer clinical trials', 0.0),\n",
       " ('Right Treatments', 'Materials and methods', 0.0),\n",
       " ('Material and Methods', 'Discussion', 0.0),\n",
       " ('Combined TIME-targeted therapy and ICP inhibitor treatment',\n",
       "  'Methods',\n",
       "  0.0),\n",
       " ('PPARs and NASH Treatments',\n",
       "  '4. Treatment Approaches to Overcome Cisplatin Resistance in Germ Cell Tumors',\n",
       "  0.0),\n",
       " ('METHODS', 'CONCLUSION', 0.0),\n",
       " ('DISCUSSION', 'FDA-Approved ICIs', 0.0),\n",
       " ('Molecular therapy', 'Conclusion', 0.0),\n",
       " ('Materials and Methods',\n",
       "  '5. From Research to Real-World Experience: Currently Approved and Clinical Development of Experimental Vaccines against Antibiotic-Resistant Bacteria',\n",
       "  0.0),\n",
       " ('Future Opportunities for GBM Therapeutics', 'The role of IL-6 in RA', 0.0),\n",
       " ('Neoadjuvant immunotherapy for operable NSCLC', 'DISCUSSION', 0.0),\n",
       " ('Results', 'Rational and evaluation of CGRP targeted therapies', 1.0),\n",
       " ('Methods', 'Introduction', 0.0),\n",
       " ('ack', 'Discussion', 0.5),\n",
       " ('article-meta', 'Materials and methods', 0.0),\n",
       " ('table-wrap', 'Results', 1.0),\n",
       " ('5. Cannabidiol: Clinical Trials for Epilepsy',\n",
       "  'FUNCTIONS AND MECHANISMS OF ACTION OF NEWLY DISCOVERED circRNAs IN OSTEOSARCOMA',\n",
       "  1.0),\n",
       " ('Methods', '2. Neural Stem Cells from the Central Nervous System', 0.0),\n",
       " ('table-wrap', 'fn-group', 0.0),\n",
       " ('Background', 'table-wrap', 0.0),\n",
       " ('Novel therapeutic strategy beyond osimertinib',\n",
       "  'NK-Cell-Based Tumor Immunotherapy',\n",
       "  0.0),\n",
       " ('Discussion', 'Patients and methods', 0.0),\n",
       " ('table-wrap', 'Methods', 0.0),\n",
       " ('Introduction', 'Cardiac AAV gene therapy: where do we stand?', 0.0),\n",
       " ('Clinical Relevance – Metabolic Targeting', 'Support for the A', 0.0),\n",
       " ('Discussion',\n",
       "  'Clinical trials about the dual inhibition of VEGF/VEGFR and PD-(L)1',\n",
       "  0.0),\n",
       " ('Evolution of the Car Design',\n",
       "  '5. Overcoming Resistance: Depicting the Future of HCC Treatment',\n",
       "  0.3333333333333333),\n",
       " ('3. Liquid Biopsy in ALK+ Cancer',\n",
       "  'Clinical Management of Glioblastoma: New Diagnosis Opportunities and Therapeutic Strategies',\n",
       "  0.5),\n",
       " ('Methods', 'article-meta', 0.0),\n",
       " ('ref-list', '2 Epigenetic Targets in Lymphoma', 0.0),\n",
       " ('DISCUSSION', 'article-meta', 0.0),\n",
       " ('CLINICAL TRIALS', 'Discussion', 0.3333333333333333),\n",
       " ('Introduction', 'Introduction', 1.0),\n",
       " ('Factors affecting lung deposition in preterm neonates',\n",
       "  '3. Adenosine Receptor Agonists—Structure, Chemical Properties, and Known Effects on Platelet Function',\n",
       "  0.3333333333333333),\n",
       " ('Introduction', 'CLINICAL STUDIES OF TARGETED NEUROBLASTOMA THERAPY', 0.0),\n",
       " ('Background', 'Clinical translation', 0.0),\n",
       " ('5. Clinical Implications of the',\n",
       "  'HGF/C-Met Signaling in Digestive System Cancers',\n",
       "  0.0),\n",
       " ('article-meta', '[H1] DEVELOPING NEW SCD THERAPIES', 0.0),\n",
       " ('Introduction', 'article-meta', 0.0),\n",
       " ('Methods', 'INTRODUCTION', 0.0),\n",
       " ('KRAS mutations and cancer', '3. Whole', 0.0),\n",
       " ('Spike Protein', 'article-meta', 0.0),\n",
       " ('METHODS', 'table-wrap', 0.0),\n",
       " ('Novel advances targeting immune factors',\n",
       "  'Early clinical trials',\n",
       "  0.3333333333333333),\n",
       " ('article-meta', '\\\\n', 0.0),\n",
       " ('table-wrap', 'INTRODUCTION', 0.0),\n",
       " ('AGN-241751 (Allergan)', 'article-meta', 0.0),\n",
       " ('2. Novel Anti-HER2 Approaches', 'RESULTS', 0.0),\n",
       " ('Cardiac Medications', 'Therapeutics for mitochondrial dysfunction', 0.0),\n",
       " ('Discussion', 'Introduction', 0.0),\n",
       " ('Management of HR-positive early stage breast cancer',\n",
       "  '2. COPD and Cardiovascular Diseases',\n",
       "  0.3333333333333333),\n",
       " ('STAR★Methods', '1. Introduction', 0.0),\n",
       " ('Anti-PD-L1/anti-PD1 agents for bladder cancer treatment',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('Results', '3 Toolkit to overcome AAV immunity', 1.0),\n",
       " ('table-wrap',\n",
       "  'Drugs in at least Phase 2 clinical development for first regulatory registration for an NTD',\n",
       "  0.0),\n",
       " ('article-meta', 'table-wrap', 0.0),\n",
       " ('Immunotherapy and Targeted Therapy', '2. Materials and Methods', 0.0),\n",
       " ('Introduction',\n",
       "  'Antimicrobial Peptides As An Alternative For Livestock Treatment',\n",
       "  1.0),\n",
       " ('Methods', 'BIOMIMETIC NANOPARTICLES', 0.0),\n",
       " ('Materials and methods',\n",
       "  '8. Small Molecule Tyrosine Kinase Inhibitors',\n",
       "  0.0),\n",
       " ('TARGETED THERAPY',\n",
       "  'Enabling technologies for precision medicine',\n",
       "  0.3333333333333333),\n",
       " ('Materials and Methods', 'STAR Methods', 1.0),\n",
       " ('4. Natural Health Products Targeting the Mitochondria', 'Methods', 0.0),\n",
       " ('1. Introduction', 'p', 0.0),\n",
       " ('Alternate Splicing in Esophageal Cancer', 'article-meta', 0.0),\n",
       " ('article-meta', 'Introduction', 0.0),\n",
       " ('Methods', 'The prospect of novel targeted therapy', 0.0),\n",
       " ('Types of ACTs', 'table-wrap', 0.0),\n",
       " ('3. Treatment', 'Discussion', 0.3333333333333333),\n",
       " ('Drugs for PD treatment under clinical trials', 'table-wrap', 1.0),\n",
       " ('The Role of Exosomes in the Diagnosis and Treatment of Diseases',\n",
       "  'Results and discussion',\n",
       "  0.0),\n",
       " ('Materials and methods', 'Results', 0.0),\n",
       " ('table-wrap', 'Covalent regulation', 0.0),\n",
       " ('Methods', 'Ethics statements', 0.5),\n",
       " ('Therapies enhanced by adjuvant nanomedicine',\n",
       "  'Tumor biomarker-based cancer therapy',\n",
       "  1.0),\n",
       " ('Background', 'MATERIALS AND METHODS', 0.0),\n",
       " ('CURRENT CLINICAL TRIALS FOR VIRAL VECTOR‐BASED IN VIVO GENE THERAPIES',\n",
       "  'New Vaccines Against TB',\n",
       "  1.0),\n",
       " ('Patients and methods',\n",
       "  'Enhancing CAR T cell proliferation and persistence',\n",
       "  0.0),\n",
       " ('Main Text', 'Ferritins in clinical trials', 0.3333333333333333),\n",
       " ('3. Cancer Immunotherapeutic Strategies',\n",
       "  'Clinical trials of anti-LAG-3, anti-TIM-3, and anti-TIGIT mAbs',\n",
       "  0.0),\n",
       " ('Methods', 'Discussion', 0.0),\n",
       " ('Results', 'Target antigen expressing on solid tumor cell surface', 0.0),\n",
       " ('METHODS', 'Introduction', 0.0),\n",
       " ('5. Current Treatment of Multiple Myeloma', 'Enfortumab Vedotin', 0.0),\n",
       " ('article-meta', 'Discussion', 0.0),\n",
       " ('app-group', 'Discussion', 0.0),\n",
       " ('Introduction', 'fn-group', 0.0),\n",
       " ('6. Management', 'table-wrap', 0.0),\n",
       " ('p', '3. Novel Combination Strategies with HMA', 0.5),\n",
       " ('4. Clinical Trials and Outcomes',\n",
       "  'Flattening the Curve With Natural Killer Cells',\n",
       "  1.0),\n",
       " ('Immune checkpoints: biological aspects and clinical studies',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('Krankheitsmodifizierende Therapieansätze', 'Methods', 0.0),\n",
       " ('Approaches to Second-Line Therapeutics',\n",
       "  'Genetic modification of oncolytic viruses',\n",
       "  0.0),\n",
       " ('Blocking STAT3 activation: targeting upstream receptors', 'ref-list', 0.5),\n",
       " ('INTRODUCTION', '1. Introduction', 0.5),\n",
       " ('Therapies available for use prior to allogeneic hematopoietic cell transplantation',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('table-wrap', '8. Mechanism of Resistance against ALK-TKI', 0.0),\n",
       " ('5. Metabolism in Therapeutic Resistance and Novel Clinical Opportunities',\n",
       "  'INSIGHTS FROM RANDOMIZED CONTROLLED TRIALS OF CALORIE RESTRICTION',\n",
       "  1.0),\n",
       " ('Conclusion', 'Discussion', 0.5),\n",
       " ('3. Literature Review and Discussion', 'Introduction', 1.0),\n",
       " ('Methods and analysis', 'Discussion', 0.0),\n",
       " ('article-meta', 'Methods', 0.0),\n",
       " ('DCregs in Clinical Organ Transplantation', 'Antimicrobials', 0.0),\n",
       " ('Enhance therapy T-cell',\n",
       "  'Strategies For Preventing Leukaemic Relapse Post CAR-T',\n",
       "  1.0),\n",
       " ('Targeting tumor microenvironments',\n",
       "  'New Agents and Isotopes: Radiolabeled Small-Molecule Binders',\n",
       "  1.0),\n",
       " ('Novel targets and combinations',\n",
       "  'Applications of TCR-based immunotherapy',\n",
       "  0.0),\n",
       " ('Clinical Applications: Immunotherapeutic Approaches to GBM',\n",
       "  'Introduction',\n",
       "  0.0),\n",
       " ('table-wrap',\n",
       "  '4. The Therapeutic Use of the Secretome in Neurological Diseases',\n",
       "  0.0),\n",
       " ('Therapies based on TGF-β signal transduction in disease',\n",
       "  'Results and discussion',\n",
       "  0.0),\n",
       " ('EHF POSTER PRESENTATIONS',\n",
       "  '4. Tissue Engineering Strategies for Articular Cartilage Regeneration',\n",
       "  0.3333333333333333),\n",
       " ('Advances in PD-1/PD-L1 blockade-based combination treatment for cancer',\n",
       "  'Study Set-Up',\n",
       "  1.0),\n",
       " ('METHODS AND TREATMENT PLAN', '4. Therapeutic Options', 0.5),\n",
       " ('ref-list', 'New therapeutic targets in ovarian cancer therapy', 0.5),\n",
       " ('3. Potential CXCL/CXCR-Based Theranostic Strategies',\n",
       "  '6. Immunotherapy for LPS',\n",
       "  0.3333333333333333),\n",
       " ('Therapies targeting inflammation in DR',\n",
       "  'Surface biomarkers have expanded significantly over the last decade',\n",
       "  1.0),\n",
       " ('2. Methods', 'Discussion', 0.0),\n",
       " ('PATIENTS AND METHODS', 'Main Text', 0.0),\n",
       " ('Methods', 'p', 0.0),\n",
       " ('Poster Presentations', 'NK cell-based therapeutic strategies', 0.0),\n",
       " ('article-meta', 'table-wrap', 0.0),\n",
       " ('Patients and methods', 'Materials and Methods', 1.0),\n",
       " ('METHODS', '2. Materials and Methods', 0.5),\n",
       " ('ref-list', 'Notch-targeted therapies', 0.3333333333333333),\n",
       " ('ref-list', 'Methods', 0.0),\n",
       " ('Introduction', 'Materials and methods', 0.0),\n",
       " ('table-wrap', 'table-wrap', 1.0),\n",
       " ('Discussion', '2. Systemic Treatment', 0.3333333333333333),\n",
       " ('ref-list', 'Epigenetic regulation and targeted therapy', 0.5),\n",
       " ('ref-list', 'Methods and analysis', 0.0),\n",
       " ('Liposomes and LLPs under clinical trials',\n",
       "  'Key considerations when combining PARPi and immune checkpoint inhibitors',\n",
       "  0.3333333333333333),\n",
       " ('Methods', 'article-meta', 0.0),\n",
       " ('Results', 'TARGETING THE GUT', 0.0),\n",
       " ('2. Systemic Therapies', 'INTRODUCTION', 1.0),\n",
       " ('Strategies to generate “off the shelf” or universal allogeneic CAR-T',\n",
       "  'Clinical trials for oral vaccines',\n",
       "  1.0),\n",
       " ('Therapeutic Approaches to Target CSCs',\n",
       "  'Other cellular immunotherapies',\n",
       "  0.0),\n",
       " ('table-wrap', 'Materials and methods', 0.0),\n",
       " ('3. Results', 'table-wrap', 0.0),\n",
       " ('fn-group', 'Results', 0.0),\n",
       " ('TREATMENT OF METASTATIC DISEASE',\n",
       "  'Targeting the PI3K Signaling and Pathway',\n",
       "  0.0),\n",
       " ('article-meta', 'Discussion', 0.0),\n",
       " ('Method', 'fn-group', 0.0),\n",
       " ('2. Adeno-Associated Virus-Based Gene Therapy',\n",
       "  'Conventional αβ T cells',\n",
       "  0.0),\n",
       " ('Tumor Microenvironment', 'Curcumin on Human Colorectal Cancer', 0.5),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('Introduction', 'table-wrap', 0.0),\n",
       " ('2. Materials and Methods', 'Materials and Methods', 1.0),\n",
       " ('Oral Presentations', 'article-meta', 0.0),\n",
       " ('Therapies',\n",
       "  'Therapies available and under investigation to target biomarkers in frontline PTCL',\n",
       "  0.5),\n",
       " ('Introduction',\n",
       "  '2. The Evolving Treatment Paradigm for Patients with Unresectable HCC',\n",
       "  0.0),\n",
       " ('4. Discussion', '2 Epigenetic Targets in Lymphoma', 0.0),\n",
       " ('Patients and Methods',\n",
       "  'Immunotherapies and DNA repair targeted therapies: Precision medicine in practice?',\n",
       "  0.0),\n",
       " ('Background', 'Exosomes in Clinical Trials', 0.3333333333333333),\n",
       " ('Alternative routes of drug delivery', 'Methods', 0.0),\n",
       " ('4. Management of RAI-R Thyroid Cancers', 'METHODS', 0.0),\n",
       " ('table-wrap', 'Patients and methods', 0.0),\n",
       " ('table-wrap', 'EMERGING TREATMENTS', 0.0),\n",
       " ('Results',\n",
       "  'Interfering with apoptosis signaling for chemoradiation sensitization',\n",
       "  0.0),\n",
       " ('Introduction', 'II. IMES History', 0.0),\n",
       " ('2. Current Treatment Options for Malignant Glioma',\n",
       "  'Result and discussion',\n",
       "  0.0),\n",
       " ('article-meta', 'Methods', 0.0),\n",
       " ('Discussion', 'Introduction', 0.0),\n",
       " ('Pathogenesis of HPS: lessons from experimental models',\n",
       "  'Introduction',\n",
       "  0.0),\n",
       " ('article-meta', 'article-meta', 1.0),\n",
       " ('Methods and analysis', 'p', 0.0),\n",
       " ('MATERIALS AND METHODS', 'table-wrap', 0.0),\n",
       " ('8. First-in-Human Clinical Studies', 'Mechanism-based approaches', 0.0),\n",
       " ('ref-list', '免疫治疗在MPM中的研究进展', 1.0),\n",
       " ('table-wrap', '2. Monoclonal Antibodies (mAbs)', 0.0),\n",
       " ('METHODS', 'Methods', 1.0),\n",
       " ('Introduction', 'Background', 0.0),\n",
       " ('RESULTS', 'notes', 0.0),\n",
       " ('DNA repair checkpoint inhibitors', 'article-meta', 0.0),\n",
       " ('Methods', 'Combinations of Targeted Therapy with Immunotherapy', 0.5),\n",
       " ('article-meta',\n",
       "  'Current approaches to tackle IFN-γ-driven resistance to ICBT',\n",
       "  0.0),\n",
       " ('4. EPLICATION-INCOMPETENT, VECTORED VACCINES', 'Discussion', 0.5),\n",
       " ('Materials and methods',\n",
       "  'Clinical outcomes for patients with urothelial and intrahepatic cholangiocarcinoma receiving FGFR inhibitors',\n",
       "  0.0),\n",
       " ('2. Neoadjuvant anti-PD-1/PD-L1 therapy according to cancer types',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('ref-list', 'table-wrap', 0.0),\n",
       " ('FERROPTOSIS‐INDUCING NATURAL PRODUCTS WITH DIVERSE MECHANISMS',\n",
       "  '4. Therapeutic Applications of mRNA',\n",
       "  0.3333333333333333),\n",
       " ('Introduction', 'Potential Targeted Therapeutic Approaches to ATRT', 0.0),\n",
       " ('Methods', 'RAS/RAF/MEK/ERK (MAPK) Signaling in Melanoma', 0.5),\n",
       " ('article-meta', 'table-wrap', 0.0),\n",
       " ('fn-group',\n",
       "  'Importtant areas of clinical applications of CTCs、ctDNA and EVs',\n",
       "  0.5),\n",
       " ('Background', 'MM Drug Targets for BsAbs', 0.0),\n",
       " ('3. Targeted Drug Therapy Designed for the Chronic Wound Microenvironment',\n",
       "  'Tumor microenvironment: The stumbling block that limits CAR-NK therapy effectiveness',\n",
       "  0.0),\n",
       " ('Introduction', 'Restoration of wild-type p53 function', 0.0),\n",
       " ('2. Materials and Methods',\n",
       "  'Specific therapeutic approaches to target B cells',\n",
       "  0.3333333333333333),\n",
       " ('Direct reactivation of the androgen receptor', 'Methods', 0.0),\n",
       " ('Other DC-Based Approaches', 'Ongoing studies', 0.0),\n",
       " ('Results', 'Immune Response Modulators', 0.0),\n",
       " ('table-wrap', 'Clinical Development of DDR Inhibitors', 1.0),\n",
       " ('ref-list', 'ref-list', 0.5),\n",
       " ('Materials and methods', '2. Pathogenesis and CMML Treatment', 0.5),\n",
       " ('Darolutamide For mCRPC: Early Drug Development',\n",
       "  'Nanotechnology in Cancer Diagnosis and Target-Specific Treatment as Phyto-Nanoformulations',\n",
       "  1.0),\n",
       " ('Immunotherapy regimens targeting RAS', 'INTRODUCTION', 0.0),\n",
       " ('table-wrap', '3 Clinical trials with SC preparations for aging', 0.0),\n",
       " ('3. Characterization of the Biology and Targeted Therapy',\n",
       "  'table-wrap',\n",
       "  0.0),\n",
       " ('CAR-T cells therapy for solid tumors', 'METHODS', 0.0),\n",
       " ('Materials and Methods', 'Methods', 0.5),\n",
       " ('ref-list', 'Materials and methods', 0.0),\n",
       " ('Materials and methods', 'Methods', 1.0),\n",
       " ('Methods', 'article-meta', 0.0),\n",
       " ('3. OX40-OX40L Inhibition',\n",
       "  '2. Vaccine candidates of the COVID-19 Turkey Platform',\n",
       "  0.0),\n",
       " ('Introduction',\n",
       "  'Novel Strategies to Potentiate PD-1/PD-L1 Blockade Immunotherapy in EGFR Mutant NSCLC',\n",
       "  1.0),\n",
       " ('Drugs approved for an NTD by at least one stringent regulatory authority',\n",
       "  'Materials and methods',\n",
       "  0.0),\n",
       " ('Immunotherapies in gliomas', 'Methods', 0.0),\n",
       " ('fn-group',\n",
       "  '5. Targeting Dormant Cancer Cell Life Cycle by the Redox-Mediated Mechanism',\n",
       "  0.5),\n",
       " ('Immunosuppression in Ovarian Cancer', 'Methods', 0.0),\n",
       " ('Which clinical trials of FMDs and STF are ongoing within clinical\\\\noncology?',\n",
       "  'article-meta',\n",
       "  0.0),\n",
       " ('Histone deacetylase inhibitors', 'Discussion', 0.5),\n",
       " ('table-wrap', '4 Innate immune sensors and recognition of SARS-CoV-2', 1.0),\n",
       " ('MATERIAL AND METHODS', 'Methods', 1.0),\n",
       " ('EMERGING THERAPIES FOR LONG TERM PROPHYLAXIS', 'Discussion', 0.0),\n",
       " ('Personalized Neoantigens-Pulsed DC Vaccines', 'ref-list', 0.0),\n",
       " ('ref-list', 'Materials and method', 0.0),\n",
       " ('Patients and Methods', 'Methods', 1.0),\n",
       " ('Introduction', 'Introduction', 0.5),\n",
       " ('Efficacy of covid-19 vaccines', '4 Discussion', 0.3333333333333333),\n",
       " ('Patients and methods',\n",
       "  'Biology of PD1 signalling and uncertainties around optimal treatment parameters',\n",
       "  0.0),\n",
       " ('A2 The effect of a vapor barrier in combination with active external rewarming for patients with accidental hypothermia',\n",
       "  'Methods',\n",
       "  0.3333333333333333),\n",
       " ('Clinical trials of Uproleselan', 'Results', 0.5),\n",
       " ('table-wrap', '5. Altered Regimen of Chemoradiotherapy Approach', 0.0),\n",
       " ('3 Novel Therapeutic Options for', 'Methods and materials', 0.0),\n",
       " ('Introduction', 'Methods', 0.0),\n",
       " ('DISCUSSION', 'Results', 0.0),\n",
       " ('Introduction', 'Clinical progress and translational implications', 0.0),\n",
       " ('Results', '3 TAM-targeting therapies for GBM', 0.0),\n",
       " ('DSC-BASED CLINICAL TRIALS FROM CLINICAL DATABASES',\n",
       "  '5. NK Cell Therapies for NSCLC',\n",
       "  0.0),\n",
       " ('3. Clinical Trials for Oligonucleotide Therapeutics in Oncology',\n",
       "  'Emerging Treatments in R/R ATL',\n",
       "  0.3333333333333333),\n",
       " ('Materials and methods', 'Discussion', 0.0),\n",
       " ('Results', 'Poster Presentations', 0.0),\n",
       " ('Therapeutic status of endocrine resistant breast cancer and new choices',\n",
       "  'Methods',\n",
       "  0.0),\n",
       " ('Organ Transplantations',\n",
       "  'Progress in mRNA cancer vaccines in preclinical and clinical settings',\n",
       "  0.0),\n",
       " ('11. Pharmacological Switches of mPTP Opening/Closing in Cancer Therapeutics',\n",
       "  'Immune compartment targeting in PDAC',\n",
       "  0.0),\n",
       " ('Signaling transduction pathways and targeted therapies', 'table-wrap', 1.0),\n",
       " ('Discussion', '2. Targeting Mutated Proteins', 0.3333333333333333),\n",
       " ('Physical activity – getting immune cells moving', 'table-wrap', 0.0),\n",
       " ('Clinical trials of XPO1/CRM1 inhibitors',\n",
       "  'Engineering the Next Generation of AAV Capsids',\n",
       "  1.0),\n",
       " ('Main Text', 'Targeting the PD1/PDL1 Pathway in TNBC', 1.0),\n",
       " ('article-meta', 'Introduction', 0.0),\n",
       " ('Results', 'notes', 0.0),\n",
       " ('Treatment of OCD patients refractory to serotonergic antidepressants\\\\n',\n",
       "  'Therapies Targeting Epicardial Fat',\n",
       "  0.3333333333333333),\n",
       " ('Exogenous T Cells for GBM', 'Methods', 0.0),\n",
       " ('Discussion',\n",
       "  'Clinical Translation of LSC metabolism targeting',\n",
       "  0.3333333333333333),\n",
       " ('CircRNAs play roles in TME regulation', 'Methods', 0.0),\n",
       " ('Categories of Repurposed Antivirals',\n",
       "  '7. Drugs in clinical trials',\n",
       "  0.3333333333333333),\n",
       " ('Generation of stem cell-derived insulin-producing cells', 'Methods', 0.0),\n",
       " ('Anti-PD-1 combined with other cancer therapeutic modalities for R/M CC',\n",
       "  'Neoantigens-based therapeutic strategies',\n",
       "  0.0),\n",
       " ('IL17 as a Central Effector in Psoriasis',\n",
       "  'THE ROLE OF AD‐MSCs IN WOUND HEALING',\n",
       "  0.0),\n",
       " ('Anti-Glycolysis Drugs That Target Innate Immune Cells',\n",
       "  'Results and Discussion',\n",
       "  0.0),\n",
       " ('Discussion', 'article-meta', 0.0),\n",
       " ('4. Discussion', 'METHODS', 0.0),\n",
       " ('RESULTS', 'Discussion', 0.0),\n",
       " ('table-wrap', 'article-meta', 0.0),\n",
       " ('Introduction', '9. SUBUNIT VACCINES', 0.0),\n",
       " ('Future Directions and the use of UCB-Derived Cells in Other Settings',\n",
       "  'Clinical trials with nanocarriers involving autophagy modulation',\n",
       "  0.0),\n",
       " ('2. Materials and Methods', 'ref-list', 0.0),\n",
       " ('Interleukin-21 implementation in clinical trials', 'table-wrap', 1.0),\n",
       " ('PREVENTION OF A FIRST EPISODE OF OHE', '3. JAK inhibitors', 0.5),\n",
       " ('4. Hh Pathway as a Therapeutic Target in AML',\n",
       "  '9. Opportunities for combinational therapy',\n",
       "  0.3333333333333333),\n",
       " ('Methods', '7. NTRK Rearrangements in Gastric Cancer', 0.5),\n",
       " ('Results', 'ref-list', 0.0),\n",
       " ('table-wrap',\n",
       "  'Targeting immune checkpoints in hematologic malignancies',\n",
       "  1.0),\n",
       " ('TKIs + Interferon-α (IFN-α)', 'table-wrap', 0.0),\n",
       " ('5 Proposed therapies to reverse the remodeling of cardiac innervation: Functional and molecular aspects',\n",
       "  'Leveraging Acellular Bioactive Scaffolds Towards Cardiac Regeneration',\n",
       "  0.5),\n",
       " ('Targeted DLL Therapy: Is It Effective and Safe?', 'article-meta', 0.0),\n",
       " ('INTRODUCTION', 'Immunotherapy', 0.0),\n",
       " ('Targeting IL-23/IL-17 pathway for the treatment of axial SpA',\n",
       "  'Material and Method',\n",
       "  0.5),\n",
       " ('STAR Methods:', 'Discussion', 0.0),\n",
       " ('Poster Presentations',\n",
       "  '3. Novel Treatment Strategies in AD',\n",
       "  0.3333333333333333),\n",
       " ('RESULTS', 'Background', 0.0),\n",
       " ('2. Materials and Methods', '“Old” Generation Immunotherapies', 0.0),\n",
       " ('Clinical applications of GCs-based prodrugs', 'Introduction', 0.0),\n",
       " ('JAK INHIBITORS',\n",
       "  '9. Bioactive Compounds Based Anti-Cancer Drugs in Clinical Trials',\n",
       "  1.0),\n",
       " ('3. Oncolytic Virotherapy for Malignant Glioma', 'notes', 0.5),\n",
       " ('Manufacturing technology',\n",
       "  'Clinical investigation of CAR-T cell therapy in solid tumors',\n",
       "  1.0),\n",
       " ('RESULTS', 'Results', 1.0),\n",
       " ('Methods', 'Methods', 1.0),\n",
       " ('Immune Responses Induced by Neoantigens',\n",
       "  'ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS',\n",
       "  0.0),\n",
       " ('table-wrap', 'Locally advanced and resectable NSCLC', 0.0),\n",
       " ('Promising agents in clinical trials for HCC', 'Introduction', 1.0),\n",
       " ('article-meta', '3. Trial Design', 0.0),\n",
       " ('Currently available reports and ongoing clinical trials of antifibrotic medications for non-IPF-PF',\n",
       "  'table-wrap',\n",
       "  1.0),\n",
       " ('CLINICAL TRIALS', 'Bispecific T-cell engagers', 0.0),\n",
       " ('Methods and analysis', 'article-meta', 0.0),\n",
       " ('Immune Reconstitution and Graft-vs.-Leukaemia Effect',\n",
       "  'Tissue-agnostic indications for immunotherapy in the treatment of GI cancer',\n",
       "  0.0),\n",
       " ('Methods', 'MATERIALS AND METHODS', 0.5),\n",
       " ('Efficacy results',\n",
       "  'Epigenetic silencing as a therapeutic target in prostate cancer',\n",
       "  0.0),\n",
       " ('Frontline Therapy', 'Background', 0.0),\n",
       " ('3. Next-Generation Selective RET Inhibitors in Clinical Development',\n",
       "  '4 Treatments for lung cancer',\n",
       "  0.3333333333333333),\n",
       " ('ref-list', 'INTERVENTION THERAPY', 0.5),\n",
       " ('RECOMMENDATIONS', 'AXL-targeted therapies', 0.0),\n",
       " ('State of clinical trials of EVs in BC theranostics', 'INTRODUCTION', 0.0),\n",
       " ('Results', '3 Targeting the DNA-damage response pathway', 0.5),\n",
       " ('8. Discussion and Future Directions', 'article-meta', 0.0),\n",
       " ...]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "training_data = []\n",
    "for ind1, ind2 in pairs:\n",
    "    training_data.append((x[ind1], x[ind2], jaccard_similarity(sections[ind1], sections[ind2])))\n",
    "training_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip show torch transformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip show sentence-transformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "from torch.utils.data import Dataset, DataLoader\n",
    "from sentence_transformers import SentenceTransformer, InputExample, losses\n",
    "\n",
    "class SentencePairDataset(Dataset):\n",
    "    def __init__(self, sentence_pairs):\n",
    "        self.samples = [InputExample(texts=[s1, s2], label=float(score)) for s1, s2, score in sentence_pairs]\n",
    "\n",
    "    def __len__(self):\n",
    "        return len(self.samples)\n",
    "\n",
    "    def __getitem__(self, idx):\n",
    "        return self.samples[idx]\n",
    "\n",
    "\n",
    "# 建立 Dataset\n",
    "train_dataset = SentencePairDataset(training_data)\n",
    "\n",
    "# sentence-transformers 需要一個特殊的 DataLoader\n",
    "train_dataloader = DataLoader(train_dataset, batch_size=16, shuffle=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "from sentence_transformers import SentenceTransformer, losses\n",
    "\n",
    "# 1. 載入預訓練模型\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "# 2. 使用 Cosine Similarity Loss\n",
    "loss = losses.AnglELoss(model)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Defaulting to user installation because normal site-packages is not writeable\n",
      "Looking in indexes: https://pypi.org/simple, https://pypi.ngc.nvidia.com\n",
      "Requirement already satisfied: datasets in /jet/home/slin23/.local/lib/python3.12/site-packages (3.2.0)\n",
      "Requirement already satisfied: filelock in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (3.13.1)\n",
      "Requirement already satisfied: numpy>=1.17 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (1.26.4)\n",
      "Requirement already satisfied: pyarrow>=15.0.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (16.1.0)\n",
      "Requirement already satisfied: dill<0.3.9,>=0.3.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (0.3.8)\n",
      "Requirement already satisfied: pandas in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (2.2.2)\n",
      "Requirement already satisfied: requests>=2.32.2 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (2.32.3)\n",
      "Requirement already satisfied: tqdm>=4.66.3 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (4.66.5)\n",
      "Requirement already satisfied: xxhash in /jet/home/slin23/.local/lib/python3.12/site-packages (from datasets) (3.5.0)\n",
      "Requirement already satisfied: multiprocess<0.70.17 in /jet/home/slin23/.local/lib/python3.12/site-packages (from datasets) (0.70.16)\n",
      "Requirement already satisfied: fsspec<=2024.9.0,>=2023.1.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from fsspec[http]<=2024.9.0,>=2023.1.0->datasets) (2024.6.1)\n",
      "Requirement already satisfied: aiohttp in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (3.10.5)\n",
      "Requirement already satisfied: huggingface-hub>=0.23.0 in /jet/home/slin23/.local/lib/python3.12/site-packages (from datasets) (0.28.1)\n",
      "Requirement already satisfied: packaging in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (24.1)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from datasets) (6.0.1)\n",
      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (2.4.0)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (1.2.0)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (23.1.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (1.4.0)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (6.0.4)\n",
      "Requirement already satisfied: yarl<2.0,>=1.0 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from aiohttp->datasets) (1.11.0)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4.3 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from huggingface-hub>=0.23.0->datasets) (4.11.0)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from requests>=2.32.2->datasets) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from requests>=2.32.2->datasets) (3.7)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from requests>=2.32.2->datasets) (2.2.3)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from requests>=2.32.2->datasets) (2024.8.30)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from pandas->datasets) (2.9.0.post0)\n",
      "Requirement already satisfied: pytz>=2020.1 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from pandas->datasets) (2024.1)\n",
      "Requirement already satisfied: tzdata>=2022.7 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from pandas->datasets) (2023.3)\n",
      "Requirement already satisfied: six>=1.5 in /opt/packages/anaconda3-2024.10-1/lib/python3.12/site-packages (from python-dateutil>=2.8.2->pandas->datasets) (1.16.0)\n"
     ]
    }
   ],
   "source": [
    "# !pip install datasets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from datasets import Dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Detected kernel version 4.18.0, which is below the recommended minimum of 5.5.0; this can cause the process to hang. It is recommended to upgrade the kernel to the minimum version or higher.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7d6d063ca18a4eb5bbcfe102726ee961",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Computing widget examples:   0%|          | 0/1 [00:00<?, ?example/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='18750' max='18750' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [18750/18750 09:27, Epoch 3/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>500</td>\n",
       "      <td>6.196600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1000</td>\n",
       "      <td>5.769000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1500</td>\n",
       "      <td>5.429100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2000</td>\n",
       "      <td>5.361600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2500</td>\n",
       "      <td>5.502200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3000</td>\n",
       "      <td>5.373000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3500</td>\n",
       "      <td>5.309500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4000</td>\n",
       "      <td>5.240300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>4500</td>\n",
       "      <td>5.248100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>5000</td>\n",
       "      <td>5.218800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>5500</td>\n",
       "      <td>5.121000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>6000</td>\n",
       "      <td>5.207000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>6500</td>\n",
       "      <td>5.087300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7000</td>\n",
       "      <td>5.012800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>7500</td>\n",
       "      <td>5.022800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>8000</td>\n",
       "      <td>5.028800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>8500</td>\n",
       "      <td>5.034200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9000</td>\n",
       "      <td>4.835400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>9500</td>\n",
       "      <td>4.906700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>10000</td>\n",
       "      <td>4.884900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>10500</td>\n",
       "      <td>4.982300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>11000</td>\n",
       "      <td>4.959200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>11500</td>\n",
       "      <td>4.792300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>12000</td>\n",
       "      <td>4.917600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>12500</td>\n",
       "      <td>4.849100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>13000</td>\n",
       "      <td>4.819700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>13500</td>\n",
       "      <td>4.661300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>14000</td>\n",
       "      <td>4.722100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>14500</td>\n",
       "      <td>4.742400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>15000</td>\n",
       "      <td>4.664700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>15500</td>\n",
       "      <td>4.731000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>16000</td>\n",
       "      <td>4.701800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>16500</td>\n",
       "      <td>4.740500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>17000</td>\n",
       "      <td>4.662400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>17500</td>\n",
       "      <td>4.761200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>18000</td>\n",
       "      <td>4.727800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>18500</td>\n",
       "      <td>4.649300</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 訓練模型\n",
    "model.fit(\n",
    "    train_objectives=[(train_dataloader, loss)],\n",
    "    epochs=3,\n",
    "    warmup_steps=100\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install transformers[torch]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(2, 384)\n"
     ]
    }
   ],
   "source": [
    "# 載入模型\n",
    "model.save(\"fine_tuned_sentence_bert_model_AnglELoss\")\n",
    "fine_tuned_model = SentenceTransformer(\"fine_tuned_sentence_bert_model_AnglELoss\")\n",
    "\n",
    "# 測試新模型\n",
    "sentences = [\"app-group\", \"Clinical trials assessing bsAbs targeting immunomodulatory checkpoints\"]\n",
    "embeddings = fine_tuned_model.encode(sentences)\n",
    "\n",
    "print(embeddings.shape)  # (2, 384) -> 2 個句子，每個有 384 維度的嵌入\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[ 0.04163747, -0.01812563, -0.01506701, -0.03651993, -0.00364399,\n",
       "        -0.00736661,  0.05641595,  0.02694586,  0.01214726, -0.00627193,\n",
       "         0.04511201, -0.05996134,  0.01921945, -0.00651108,  0.04098387,\n",
       "         0.04525718, -0.05798994,  0.04601544, -0.02428723, -0.06652851,\n",
       "        -0.03902736,  0.03031879,  0.09346688,  0.04533965,  0.0067825 ,\n",
       "         0.04427031, -0.08998861,  0.02316422,  0.0838801 ,  0.00605553,\n",
       "         0.04548264, -0.02715932, -0.02285313,  0.03773755, -0.03267668,\n",
       "         0.05948149,  0.01880023, -0.11110268, -0.03138827, -0.02779789,\n",
       "         0.06593427,  0.07478728, -0.04996443,  0.1065045 , -0.08972514,\n",
       "        -0.03793259,  0.01137837,  0.04462018,  0.00310187,  0.06228391,\n",
       "         0.1306292 , -0.01950498,  0.01533441,  0.06914211,  0.01997553,\n",
       "         0.06133073, -0.02074998,  0.01316621, -0.02336246,  0.02454231,\n",
       "         0.04532381,  0.00448275,  0.0292798 ,  0.03403847, -0.02719993,\n",
       "         0.06238527, -0.01776674,  0.02869806,  0.02777211, -0.04970375,\n",
       "         0.03606734,  0.01318269,  0.05027339, -0.05753759, -0.05566981,\n",
       "        -0.07107275, -0.03552134,  0.04324009, -0.08007398, -0.06820522,\n",
       "         0.01036732, -0.02362649, -0.0747311 ,  0.07774787,  0.01778243,\n",
       "        -0.00943752,  0.01665144, -0.06425875, -0.01471203,  0.05225896,\n",
       "        -0.04013379,  0.02845586,  0.09318633, -0.00441718,  0.02234027,\n",
       "        -0.03373347, -0.01004344,  0.03470044, -0.06152182,  0.06950893,\n",
       "         0.02294112, -0.0673411 ,  0.02164492, -0.03425356,  0.01283425,\n",
       "        -0.04921413, -0.07112712, -0.10402109, -0.07370254,  0.02268276,\n",
       "        -0.0281643 ,  0.00973584,  0.05895923,  0.01966102, -0.01927124,\n",
       "        -0.04911056,  0.05941565,  0.0316417 , -0.01122185,  0.08153179,\n",
       "        -0.01344761, -0.00839538,  0.00444862, -0.03115816,  0.07495171,\n",
       "        -0.00436098, -0.04391092, -0.00041129, -0.03349492, -0.0528559 ,\n",
       "        -0.0055371 ,  0.02985994, -0.0176903 , -0.05368272, -0.030861  ,\n",
       "         0.09636508, -0.09696415, -0.04331192, -0.00942159,  0.04135383,\n",
       "        -0.06956431, -0.03698344,  0.04696008,  0.0662246 , -0.07006261,\n",
       "         0.02782832,  0.0180852 , -0.01889942, -0.09572572, -0.02276769,\n",
       "        -0.08130033,  0.02149294, -0.07640268,  0.02176509,  0.05259117,\n",
       "        -0.05980401, -0.03069775,  0.0100015 ,  0.02129204,  0.06024203,\n",
       "        -0.06744978,  0.02055516, -0.01085554, -0.00944398,  0.042388  ,\n",
       "         0.06434123, -0.02683857,  0.08912049, -0.06411266,  0.0033743 ,\n",
       "         0.03987147,  0.00384964,  0.01450527,  0.05156763,  0.02435612,\n",
       "        -0.05574316, -0.06083668, -0.01255893, -0.0055659 , -0.04557789,\n",
       "        -0.0218433 ,  0.01409791, -0.02935117, -0.10723868, -0.0272482 ,\n",
       "         0.00225006, -0.06427974, -0.11968479,  0.02502685, -0.00882628,\n",
       "        -0.04608676,  0.03156192, -0.03815658,  0.09165926,  0.06572583,\n",
       "         0.01209987, -0.03867611,  0.0061103 , -0.05145191,  0.04370056,\n",
       "         0.03366918,  0.04289919, -0.05964091,  0.039403  ,  0.09256263,\n",
       "         0.06039253, -0.0627143 , -0.02596628,  0.00558136, -0.04461235,\n",
       "        -0.00991026, -0.02244949, -0.0561353 ,  0.09123527,  0.02858249,\n",
       "        -0.08724632, -0.05330308,  0.0628241 , -0.08251276,  0.02109487,\n",
       "         0.10056457, -0.0135073 , -0.03634956,  0.00068854,  0.01942482,\n",
       "         0.05419409, -0.00907927, -0.02630178,  0.08058003, -0.03316067,\n",
       "         0.00483232,  0.03544952,  0.02544517,  0.07058503, -0.06670328,\n",
       "        -0.03580514,  0.04963961,  0.02975081, -0.05973281,  0.05839462,\n",
       "         0.02990142,  0.04467681,  0.11333708,  0.00299998, -0.05307273,\n",
       "        -0.02394816,  0.0448051 ,  0.00917143,  0.01357234, -0.06399088,\n",
       "         0.03464513, -0.10907944,  0.02670141, -0.02373497,  0.00131354,\n",
       "        -0.0688066 , -0.0237153 , -0.10751048, -0.10045832, -0.02433967,\n",
       "        -0.05527884,  0.04522798,  0.03172839, -0.03544682, -0.02100023,\n",
       "        -0.0303967 ,  0.02898598, -0.02372467, -0.01567342, -0.02561862,\n",
       "         0.03599634, -0.05627012, -0.13004786,  0.03470979,  0.02699499,\n",
       "         0.09130607,  0.02259041,  0.00442465,  0.00782948,  0.08784998,\n",
       "         0.16955626, -0.00884534, -0.11400305,  0.02680416,  0.02128462,\n",
       "        -0.01070823,  0.01633032, -0.03708396,  0.03366587, -0.03353696,\n",
       "         0.00286739, -0.01119535, -0.04050838,  0.03306267, -0.03674063,\n",
       "        -0.04632162, -0.00994238,  0.04326008, -0.12560672,  0.04906132,\n",
       "         0.08213422, -0.0363676 , -0.05133567, -0.0221416 , -0.0949958 ,\n",
       "         0.02649102,  0.02877746,  0.01560411, -0.07150842, -0.01776618,\n",
       "        -0.03919409,  0.00121211,  0.02186421,  0.04594556,  0.03893614,\n",
       "         0.07634439,  0.06311887, -0.03408653, -0.06721411,  0.00134476,\n",
       "         0.01678322,  0.02952137, -0.06241086, -0.0491902 , -0.02921046,\n",
       "        -0.05231859, -0.0506504 ,  0.05375564,  0.12116927, -0.02945628,\n",
       "        -0.11470006,  0.03972268, -0.15293095,  0.00870054, -0.00636376,\n",
       "         0.03132144, -0.0204511 ,  0.01235075,  0.00078381,  0.01178961,\n",
       "        -0.00069923, -0.02845905,  0.00746184,  0.02852879,  0.05257654,\n",
       "        -0.0415062 ,  0.0228807 , -0.06633723, -0.03573634, -0.00905384,\n",
       "         0.00277696,  0.04610563,  0.01368746,  0.03141521,  0.02195461,\n",
       "         0.03436869, -0.00770624,  0.11805988,  0.03762762, -0.04429318,\n",
       "         0.0087393 , -0.0559143 ,  0.06717648, -0.01053609, -0.0148475 ,\n",
       "        -0.01503816,  0.0501183 , -0.04149557,  0.1258866 ,  0.08260299,\n",
       "         0.04163797,  0.02992917, -0.03225715, -0.01699122,  0.01179131,\n",
       "         0.09621079, -0.00865574, -0.08438728,  0.0586594 , -0.04968818,\n",
       "         0.02301149, -0.00536893, -0.090282  ,  0.01832241],\n",
       "       [-0.02226765, -0.03972125, -0.06614824,  0.04401989, -0.00295503,\n",
       "         0.00474304,  0.00523942, -0.05152713, -0.04177096, -0.04663435,\n",
       "        -0.02630335, -0.0156378 ,  0.04955455, -0.08932479,  0.01121086,\n",
       "         0.08749508,  0.05085826,  0.00214707,  0.00672762,  0.02454208,\n",
       "         0.03178371,  0.06941569,  0.03590205,  0.07842711, -0.01836693,\n",
       "        -0.01486758, -0.01727251, -0.05986197, -0.01523552, -0.01345555,\n",
       "         0.00450015, -0.04707037, -0.06796724, -0.00793188,  0.04657779,\n",
       "        -0.04571987, -0.00323279,  0.07638933, -0.03282075, -0.06146905,\n",
       "         0.03189429,  0.0469114 , -0.05601019, -0.07011957, -0.02144202,\n",
       "        -0.03729469, -0.01137857, -0.0350983 ,  0.03893747, -0.02012077,\n",
       "        -0.01816409, -0.10012683,  0.02582041,  0.04308306, -0.04105606,\n",
       "        -0.09616157,  0.00555548, -0.07307389,  0.03209572, -0.0279226 ,\n",
       "        -0.06057074, -0.01438946,  0.06269393,  0.00426293,  0.13883781,\n",
       "         0.09913968, -0.07686768, -0.09354879, -0.07947442, -0.03689653,\n",
       "        -0.06735525, -0.07312921, -0.0013094 ,  0.00871877,  0.05403079,\n",
       "        -0.04416065,  0.02337534,  0.0729629 ,  0.05921834,  0.01117993,\n",
       "        -0.01693817, -0.06809298, -0.04807211,  0.07523774, -0.06416135,\n",
       "         0.01055274,  0.00625967, -0.01219026, -0.0138685 , -0.03517185,\n",
       "         0.04073611,  0.0234528 , -0.07934958, -0.03584126, -0.00338715,\n",
       "        -0.05097834, -0.03171139,  0.0216662 ,  0.0451383 , -0.01673446,\n",
       "        -0.08451173, -0.06127065, -0.0021605 , -0.0355079 , -0.03906373,\n",
       "         0.02872982, -0.00963642, -0.02867705,  0.04561273, -0.002292  ,\n",
       "         0.04027817, -0.01486421,  0.07762402,  0.06173445,  0.02647317,\n",
       "        -0.03219771, -0.03768952, -0.0166329 ,  0.0291281 , -0.07000375,\n",
       "        -0.00922901,  0.10181554,  0.08257607, -0.02519677,  0.01697811,\n",
       "        -0.00745622,  0.1230586 ,  0.00447952,  0.10911117,  0.03012183,\n",
       "         0.01131574,  0.02396853,  0.02061388,  0.03274206, -0.07960794,\n",
       "        -0.00958239, -0.02186429,  0.03618813, -0.02173373, -0.04535391,\n",
       "         0.01050945, -0.02280113,  0.04871702,  0.06657728, -0.06444711,\n",
       "         0.00126599,  0.03559902,  0.00913179,  0.05264501, -0.04003125,\n",
       "        -0.07404838,  0.0800813 , -0.01086774,  0.06367239, -0.00090507,\n",
       "         0.03246862, -0.05667313,  0.01128808,  0.00630029,  0.08388647,\n",
       "        -0.04814726, -0.01617756, -0.00082368,  0.03747217, -0.07385076,\n",
       "         0.06451298, -0.08013686, -0.09337723,  0.01048335, -0.03643883,\n",
       "        -0.07577977,  0.03919405,  0.07889757, -0.03026148,  0.08263999,\n",
       "         0.03523367,  0.0072185 , -0.03571306, -0.06274205, -0.03109827,\n",
       "         0.04786638,  0.0486772 ,  0.09931964,  0.0522128 ,  0.1439647 ,\n",
       "         0.03295148,  0.02088237,  0.05094524,  0.11886574,  0.0101805 ,\n",
       "        -0.04542448,  0.01795294,  0.0255738 , -0.00752126,  0.05574486,\n",
       "         0.10601366, -0.05733605, -0.0888296 ,  0.02659632, -0.03120154,\n",
       "         0.05547716,  0.0330034 , -0.05323533, -0.01100689,  0.03713864,\n",
       "         0.00132387, -0.06605224,  0.00666653, -0.03016838, -0.1235098 ,\n",
       "        -0.02702508, -0.00359696,  0.03783708, -0.06924365,  0.01115941,\n",
       "        -0.06373182, -0.01507349, -0.13590932, -0.02982199, -0.04118165,\n",
       "        -0.0955053 ,  0.01033915, -0.01046025,  0.00131092,  0.02216824,\n",
       "        -0.0019314 ,  0.04752686,  0.00822556,  0.01841736, -0.13994206,\n",
       "         0.04715578, -0.02347623, -0.00598451, -0.00695307, -0.06056294,\n",
       "        -0.06075126, -0.01415315, -0.02780266,  0.03463237, -0.03244665,\n",
       "         0.02747193, -0.03411161, -0.02991445, -0.01872217,  0.04244114,\n",
       "         0.10657008,  0.0136005 , -0.01974424,  0.04794067,  0.00041983,\n",
       "         0.06676604,  0.19437371,  0.02368124,  0.05499304,  0.05138033,\n",
       "         0.08894873,  0.08671291, -0.04332751, -0.02218393,  0.00143206,\n",
       "        -0.0319603 ,  0.0179204 ,  0.11518658,  0.01121894, -0.05037674,\n",
       "         0.03233652, -0.08116739, -0.08107387,  0.05567352,  0.07062101,\n",
       "        -0.08413725,  0.02370447, -0.07813913, -0.0426983 ,  0.03468802,\n",
       "         0.03335575,  0.04153941,  0.02755346, -0.00953746, -0.02519299,\n",
       "        -0.07071075,  0.04016195,  0.02796388, -0.06922483,  0.02748722,\n",
       "         0.06334726,  0.05505035,  0.04194723, -0.07990173,  0.01284014,\n",
       "        -0.01577325, -0.04829912,  0.04477553,  0.05038195, -0.04805024,\n",
       "        -0.00070107, -0.03811952,  0.07230985, -0.00149182,  0.05713573,\n",
       "        -0.06029248,  0.00900292, -0.00670665,  0.00843861, -0.09294679,\n",
       "         0.02329464,  0.03869491,  0.03689757,  0.02225537,  0.05628953,\n",
       "        -0.09114098, -0.01046306,  0.00944876,  0.018775  , -0.11391523,\n",
       "         0.00060531,  0.02969506,  0.01226028, -0.07645499,  0.0022877 ,\n",
       "        -0.06148825,  0.0084111 ,  0.05792494,  0.0389052 ,  0.08222386,\n",
       "         0.00621852, -0.04455872, -0.04435873, -0.03972676, -0.00063186,\n",
       "        -0.05626437, -0.00601748, -0.03531188,  0.03200121, -0.03517656,\n",
       "         0.01387036,  0.03255171, -0.07412082, -0.02134147, -0.03501544,\n",
       "         0.05124573, -0.01663383,  0.08268949, -0.0363002 , -0.03942487,\n",
       "         0.01776593, -0.00640645,  0.01773098,  0.00902493,  0.00158541,\n",
       "         0.04995752,  0.01189678,  0.05497722, -0.06979959, -0.08187768,\n",
       "         0.00497891, -0.06924318,  0.04483486,  0.03600705,  0.05510272,\n",
       "        -0.0083193 , -0.03800362,  0.02229697, -0.0250996 , -0.04921689,\n",
       "         0.01565829, -0.07257316,  0.05201843,  0.02647666, -0.00608853,\n",
       "         0.0276842 , -0.08107695, -0.07576455,  0.04229914, -0.01086323,\n",
       "        -0.00681533,  0.00412205, -0.02248111,  0.05070624,  0.00935007,\n",
       "         0.01344343, -0.05644788,  0.04085663, -0.0663297 ]],\n",
       "      dtype=float32)"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embeddings"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.21"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
